The antioxidant capacity of subjects with Gilbert syndrome by Ertl, Anita
1 
 
 
 
DIPLOMARBEIT 
Titel der Diplomarbeit 
„The antioxidant capacity of subjects with         
Gilbert syndrome“ 
 
Verfasserin 
Anita Ertl 
angestrebter akademischer Grad 
Magistra der Naturwissenschaften (Mag.rer.nat.) 
Wien, November 2012  
Studienkennzahl lt. Studienblatt: A 474 
Studienrichtung lt. Studienblatt: Ernährungswissenschaften 
Betreuer: Univ.-Prof. Dr. Karl-Heinz Wagner 
  
DANKSAGUNG 
 
Ich möchte mich besonders herzlich bei Herrn Ao. Univ.-Prof. Dr. Karl-Heinz 
Wagner bedanken, ohne dessen freundliche Betreuung und geduldige 
Hilfestellung ich diese Arbeit nicht hätte vollenden können. 
Weiteres danke ich Frau Mag. Marlies Wallner für ihre tatkräftige Unterstützung 
im Labor und ihre stetige Hilfsbereitschaft in allen Lebenslagen.  
Mein Dank geht ebenso an Frau Mag. Elisabeth Müllner die mir immer 
bereitwillig mit Rat und Tat zur Seite stand. 
Ein großes Dankeschön geht an meine Kolleginnen Admira Plavotic und 
Alexandra Kauril für die gute Zusammenarbeit und nette Gesellschaft. 
Ganz besonders möchte ich meinem Freund Sebastian, meiner Mama und 
meiner Schwester Rita danken, ohne deren seelischer Unterstützung und 
Beistand ich verloren gewesen wäre! Ihr seid die Besten und ohne Euch hätte 
ich aufgegeben! 
Zu guter Letzt danke ich meiner lieben Freundin Gitti, meiner Schwester Astrid, 
meinen Nichten Pia und Lena, sowie meiner gesamten Familie, die mich stets 
aufgemuntert und motiviert haben. 
 
 
 
 
 
 
I 
 
1 Introduction ................................................................................................ 1 
2 Literature Review ....................................................................................... 2 
2.1 Oxidative stress and free radical metabolism ........................................ 2 
2.1.1 Free radicals ................................................................................... 2 
2.1.2 Antioxidants ..................................................................................... 3 
2.1.3 Oxidative stress ............................................................................... 4 
2.1.4 Lipid peroxidation ............................................................................ 5 
2.1.4.1 MDA as a biomarker for oxidative stress...................................... 6 
2.1.5 Methods to measure the oxidative capacity .................................... 6 
2.1.5.1 Chemical backround .................................................................... 8 
2.2 Bilirubin ................................................................................................ 11 
2.2.1 Structure ........................................................................................ 11 
2.2.2 Heme catabolism........................................................................... 12 
2.2.3 Physiological concentrations of bilirubin ........................................ 14 
2.2.4 Relevance of bilirubin as an antioxidant ........................................ 14 
2.3 Inherited forms of unconjugated hyperbilirubinemia ............................ 16 
2.3.1 Morbus Gilbert ............................................................................... 16 
2.3.1.1 GS in ethnic groups ................................................................... 18 
2.3.1.2 GS in neonates .......................................................................... 19 
2.3.1.3 Symptoms and Treatment .......................................................... 20 
2.3.1.4 Methods to diagnose GS ............................................................ 21 
2.3.1.4.1 The “caloric restriction” or “starving test” ............................... 21 
2.3.1.4.2 The nicotinic acid provocation test ........................................ 21 
2.3.1.4.3 Overnight Rifampin Test ....................................................... 22 
2.3.1.4.4 Fractionation via thin-layer chromatoghraphy ....................... 22 
2.3.1.4.5 Genetic testing ...................................................................... 23 
II 
 
2.3.2 Crigler-Najjar-Syndrom.................................................................. 23 
2.3.3 GS and Cardiovascular diseases .................................................. 24 
3 Materials and Methods ............................................................................. 26 
3.1 Study design ........................................................................................ 26 
3.1.1 Required criteria for subjects ......................................................... 26 
3.1.2 Classification of the participants .................................................... 27 
3.1.3 Subject recruitment ....................................................................... 28 
3.1.4 Blood preparation .......................................................................... 28 
3.2 ORAC – Oxygen Radical Absorbance Capacity .................................. 29 
3.2.1 The Principle of ORAC .................................................................. 29 
3.2.2 Reagents and Instruments ............................................................ 31 
3.2.3 Instrument settings ........................................................................ 33 
3.2.4 Work plan for the ORAC assay ..................................................... 35 
3.2.5 Processing of data ........................................................................ 36 
3.2.6 Quality assurance ......................................................................... 37 
3.3 FRAP – Ferric Reducing Ability of Plasma .......................................... 38 
3.3.1 The Principle of FRAP ................................................................... 38 
3.3.2 Reagents and Instruments ............................................................ 39 
3.3.3 Instrument settings ........................................................................ 41 
3.3.4 Work plan for the FRAP assay ...................................................... 42 
3.3.5 Processing of data ........................................................................ 43 
3.3.6 Quality assurance ......................................................................... 44 
3.4 Malondialdehyd (MDA) ........................................................................ 44 
3.4.1 The Principle of MDA .................................................................... 44 
3.4.2 Reagents and Instruments ............................................................ 45 
3.4.3 Instrument settings ........................................................................ 46 
III 
 
3.4.4 Implementation .............................................................................. 47 
3.4.5 Calculation .................................................................................... 47 
3.4.6 Quality assurance .......................................................................... 47 
3.5 Statistical evaluation ............................................................................ 48 
4 Results and Discussion ........................................................................... 48 
4.1 Study characteristics ............................................................................ 48 
4.2 Evaluation of the used methods ORAC, FRAP and MDA .................... 49 
4.2.1 Differences between the GS and control group ............................. 50 
4.2.2 UCB (unconjugated bilirubin) in Tertiles ........................................ 51 
4.2.3 UCB in Quartiles............................................................................ 52 
4.2.4 Differences between the genders .................................................. 53 
4.2.5 Differences between 2 groups BMI ............................................... 54 
4.2.5.1 Differences between GS and C group divided in 2 groups BMI . 55 
4.2.6 Differences between age in 2 groups ............................................ 55 
4.2.6.1 Differences between GS and C group divided in 2 age groups .. 56 
4.3 Correlations ......................................................................................... 56 
4.3.1 Correlations with ORAC ................................................................ 57 
4.3.1.1 ORAC and UCB ......................................................................... 57 
4.3.1.2 ORAC and uric acid ................................................................... 57 
4.3.1.3 ORAC and BMI .......................................................................... 58 
4.3.2 Correlations with FRAP ................................................................. 59 
4.3.2.1 FRAP and UCB .......................................................................... 59 
4.3.2.2 FRAP and Albumin .................................................................... 60 
4.3.3 Correlations with MDA ................................................................... 61 
4.3.3.1 MDA and UCB ........................................................................... 61 
4.3.3.2 MDA and high density lipoprotein (HDL) .................................... 62 
IV 
 
4.3.3.3 MDA and total cholesterol (TCH) ............................................... 64 
5 Conclusion ................................................................................................ 66 
6 Summary ................................................................................................... 67 
7 Zusammenfassung ................................................................................... 68 
8 Bibliography ............................................................................................. 69 
9 Curriculum Vitae ....................................................................................... 86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V 
 
 
List of Tables 
 
Tab. 1: List of extracellular antioxidants .............................................................. 4 
Tab. 2: List of primary and secondary antioxidants  ............................................ 4 
Tab. 3: Reagents and Instruments for the ORAC test ....................................... 31 
Tab. 4: Basic Instrument settings ORAC .......................................................... 33 
Tab. 5: Pipetting schemata for ORAC ............................................................... 34 
Tab. 6: First half of Microplate for ORAC .......................................................... 35 
Tab. 7: Second half of Microplate for ORAC ..................................................... 35 
Tab. 8: Accuracy of the ORAC analyzing .......................................................... 38 
Tab. 9: Reagents and Instruments for the FRAP test ....................................... 39 
Tab. 10: Basic Instrument settings FRAP ......................................................... 41 
Tab. 11: Pipetting schemata FRAP ................................................................... 41 
Tab. 12: Layout for the 96-well Microplate FRAP .............................................. 42 
Tab. 13: Layout for the 96-well Microplate FRAP .............................................. 43 
Tab. 14: Accuracy of FRAP .............................................................................. 44 
Tab. 15: Reagents and instrumens for MDA ..................................................... 45 
Tab. 16: Basic Instrument settings MDA ........................................................... 46 
Tab. 17: Pipetting schemata for MDA ............................................................... 47 
Tab. 18: Accuracy of MDA ................................................................................ 48 
Tab. 19: Study characteristics of the GS and control group .............................. 49 
Tab. 20: Average UCB concentrations and ranges in GS and control group .... 49 
Tab. 21: ORAC, FRAP and MDA levels in GS and control group ..................... 50 
Tab. 22: ORAC, FRAP and MDA levels divided into UCB tertiles ..................... 51 
Tab. 23: ORAC, FRAP and MDA levels divided into UCB-quariles ................... 52 
Tab. 24: ORAC, FRAP and MDA levels divided into genders ........................... 53 
VI 
 
Tab. 25: ORAC, FRAP and MDA levels divided into 2 BMI groups .................. 54 
Tab. 26: ORAC, FRAP and MDA levels in GS, control and 2 BMI groups ........ 55 
Tab. 27: ORAC, FRAP and MDA levels divided into 2 age groups ................... 56 
Tab. 28: ORAC, FRAP and MDA levels in GS, control and 2 age groups ........ 56 
Tab. 29: Correlation between ORAC and uric acid ........................................... 57 
Tab. 30: Correlation between FRAP and UCB in various groups ..................... 59 
Tab. 31: Correlations between FRAP and Albumin in various groups .............. 60 
Tab. 32: Correlation between MDA and HDL in various groups ....................... 62 
Tab. 33: Correlation between MDA and HDL in various groups ....................... 64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VII 
 
 
List of Figures 
 
Fig. 1: Oxidative Stress ....................................................................................... 5 
Fig. 2: Structure of Bilirubin IXa ........................................................................ 11 
Fig. 3: Bilirubin metabolism ............................................................................... 13 
Fig. 4: Ribbon diagram of the predicted 3D structure of UGT1A1 ..................... 17 
Fig. 5: Nucleotide sequence of the BGT gene promoter ................................... 18 
Fig. 6: Classification of participants ................................................................... 27 
Fig. 7: Principle of the ORAC assay .................................................................. 30 
Fig. 8: Illustration of Net AUC (ORAC) .............................................................. 36 
Fig. 9: Linear plot of Trolox concentrations vs. the Net AUCs ........................... 37 
Fig. 10: Reaction of FRAP ................................................................................ 38 
Fig. 11: Illustration of the Iron(II)-standard curve (FRAP) ................................. 43 
Fig. 12: Illustration of the Trolox-curve (FRAP) ................................................. 44 
Fig. 13: Difference of the FRAP levels between GS and controls group ........... 50 
Fig. 14: FRAP values according to the different UCB tertiles ............................ 52 
Fig. 15: Correlation between ORAC and uric acid  ........................................... 57 
Fig. 16: Correlation of ORAC and BMI .............................................................. 58 
Fig. 17: The relationship between FRAP and UCB ........................................... 59 
Fig. 18: Correlation between FRAP and albumin .............................................. 60 
Fig. 19: Correlation between MDA and HDL ..................................................... 63 
Fig. 20: Correlation between TCH and MDA ..................................................... 64 
 
 
 
 
VIII 
 
List of Abbreviations 
 
GS Gilbert’s syndrome 
FRAP Ferric reducing ability of plasma 
ORAC  Oxygen radical absorbance capacity 
MDA  Malondialdehyde 
ROS Reactive oxygen species 
H2O2 hydrogen peroxide 
O2 oxygen 
O2* superoxide radical 
NO* nitric oxide 
RNS reactive nitrogen species 
NO2* nitrogen dioxide 
ONOO* peroxynitrite 
NOS2 nitric oxide synthase 2 
NOX nicotinamide adenine dinucleotide phosphate- 
 oxidase 
OH* Hydroxyl radicals 
R* carbon-centred radical 
RO* alkoxyl radical 
ROO* peroxyl radical 
DNA Deoxyribonucleic acid 
GSH Glutathione 
GSSG Glutathione disulfide 
4-HNE 4-hydroxynonenal 
LPO lipid peroxidation 
IX 
 
 
CVD cardio vascular diseases 
PUFAs polyunsaturated fatty acids 
HAT hydrogen atom transfer 
SET single electron transfer 
H hydrogen 
TEAC Trolox equivalence antioxidant capacity assay 
TOSCA Total oxyradical scavenging capacity assay 
PRAC Cupric ions (Cu2+) reducing antioxidant power  
 assay 
ABTS*+ 2,2-Azinobis 3-etylbenzthiazoline-6-sulphonic  
 acid radical scavenging  assay 
DPPH* 2,2-Diphenyl-1-picrylhydrazyl radical  
 scavenging 
DMPD*+ N,N-dimethyl-p-phenylenediamine radical  
 scavenging assay 
HMOX heme oxygenase 
CN Crigler-Najjar 
LDL low density lipoprotein 
LOO* lipid-peroxyl radicals 
LOOH lipid hydroperoxide 
UDPGT Uridine 5'-diphospho (UDP)- 
 glucuronosyltransferase 
AEP Appropriateness Evaluation Protocol 
HDL high density lipoprotein 
EDTA ethylene-diamin-etetraacetic-acid 
AAPH 2,2’-azobis 2-amidinopropane dihydrochloride 
X 
 
AUC area under the curve 
SD standard deviation 
CV% coefficient of variation 
TBA thiobarbituric acid 
HPLC high-performance liquid chromatography 
Fe Iron 
TPTZ Tripyridyltriazin 
HDL h igh density lipoprotein 
TCH total cholesterol 
AHA American Health Association 
 
1 
 
 
1 Introduction 
This thesis was conducted within the framework of the project “Antioxidative 
and Antigenotoxic Potential of Bile Pigments”, facilitated by FWF-Austrian 
Science Fund. The research was executed at the Department of Nutritional 
Sciences, situated at the University of Vienna.  
Bilirubin, a yellow colored bile pigment formed by the heme catabolism, was 
proven to exhibit a potential antioxidant activity, due to the ability to scavenge 
overproduced reactive oxygen species (ROS) and thus protects against 
oxidative stress damage, primarily increased DNA damage. In particular, lipid 
peroxidation, which is responsible for cell aging and the development of chronic 
diseases including cardiovascular diseases (CVD) and cancer is inhibited by 
albumin-bound bilirubin. There is a multitude of studies focused on the 
association between an elevated circulation of bilirubin and the prevalence of 
diseases resulting from oxidative damage.  
Gilbert’s syndrome (GS), a relatively common condition which applies to 
approximately 3-10% of the general population, is a benign form of mild 
unconjugated hyperbilirubinemia, caused by a 70% reduction of the 
glucuronidation of bilirubin, catalyzed by the uridine-diphosphate-
glucuronosyltransferase (UGT1A1). Based on the resulting elevated bilirubin 
level GS subjects have a reduced susceptibility for the formation of oxidative 
damage and moreover, a lower prevalence for the subsequent development of 
diseases. 
The aim of the following research project was to investigate whether or not 
individuals with GS, compared to a healthy control group, do indeed show a 
diminished oxidative stress potential as a result of an elevated bilirubin level 
and therefore have minor oxidative stress damage. The antioxidant capacity 
was determined by the antioxidant capacity assays FRAP (Ferric reducing 
ability of plasma) and ORAC (Oxygen radical absorbance capacity) as well as 
by the measurement of MDA (Malondialdehyde), a biomarker for oxidative 
stress. 
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2 Literature Review 
2.1 Oxidative stress and free radical metabolism  
2.1.1 Free radicals 
Free radicals are highly unstable atoms or molecules, which contain one or 
more unpaired electrons in its orbital and are therefore extremely reactive. Due 
to free radical’s affinity to absorb electrons from adjacent molecules to stabilize 
itself, they have the tendency to proceed as a chain reaction due to the 
subsequent transformation of the non-radical donor to a radical. [CLARKSON 
and THOMSON, 2000] Various types of free radicals react in different ways and 
have a more potent reactive effect compared to non-radicals. [HALLIWELL et 
al., 1995] These chemically reactive molecules are linked to oxygen and known 
as reactive oxygen species (ROS) in contrast to non-radical species, for 
example, hydrogen peroxide (H2O2). Oxygen (O2) exhibits two unpaired 
electrons and therefore, theoretically constitutes as a free radical. However, 
based on a specific electron arrangement, the reactivity is restricted. 
[HALLIWELL and GUTTERIDGE, 1990]  
ROS emerge from endogenous as well as exogenous sources. However, the 
most common is the production of the by-product superoxide radical (O2*), and 
it takes place in the mitochondria of the cell. When combined, O2* and nitric 
oxide (NO*) are highly reactive and generate reactive nitrogen species (RNS), 
such as NO*, nitrogen dioxide (NO2*) and peroxynitrite (ONOO*), due to the 
activity of nitric oxide synthase 2 (NOS2) and NADPH oxidase (NOX). Hydroxyl 
radicals (OH*) are also highly reactive and attack numerous molecules in the 
nearby environment. Alongside OH*, gaseous NO2* and NO* free radicals also 
include the carbon-centred (R*), alkoxyl (RO*), and peroxyl radical (ROO*), 
which all generate from lipid peroxidation. [HALLIWELL et al., 1995]  
Beyond the involvement in cell signaling and homeostasis, increased levels of 
ROS alter lipid, protein, and DNA structures and subsequently initialize cell 
aging, toxic exposure, radiation damage and diseases. [DEVASAGAYAM et al. 
2004] However, free radicals are involved in major physiological functions 
including the production of O2* by activated phagocytic cells in order to 
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eliminate bacteria, fungi and viruses. [CURNUTTE and BABIOR, 1987] To 
avoid a damaging impact of ROS, cells feature a number of defense 
mechanisms to prevent or limit intracellular damage including antioxidants such 
as Vitamin E, ascorbic acid, glutathione and antioxidant enzymes, such as 
superoxide dismutase, glutathione peroxidase and catalase. Therefore, 
physiological ROS levels are held at a low rate. [HARRISON et al., 2005] 
2.1.2 Antioxidants 
Antioxidants are defined as molecules which limit the transfer of electrons from 
a free radical to a non-radical, hence oxidation. Moreover, the antioxidant 
defense systems protect against radical damages in organisms and therefore 
reduce the ROS load and defuse it to less reactive products. [SIES, 1997] 
Antioxidants found in the human body are distinguished between extracellular 
and intracellular due to their location. Intracellular enzymatic antioxidants, such 
as superoxide dismutase, glutathione peroxidase and catalase regulate the 
reactive potential of substrates in the body. Extracellular antioxidants, such as 
albumin, transferrin and lactoferrin inhibit the radical reaction of metal ions by 
inducing a complex formation in the organism. [GUTTERIDGE, 1995] Non-
enzymatic antioxidants are proteins, vitamins and provitamins, flavonoids, 
polyphenols, peptides with thiol groups, ubiquinone and uric acid. [POWERS et 
al., 2004] Furthermore, bilirubin, urate and albumin are able to scavenge free 
radicals directly. A variety of antioxidants are provided by food such as lipophilic 
vitamins including vitamin E, carotenoids, water-soluble vitamin C and 
Selenium, which affects the activity of glutathione peroxidase. [GUTTERIDGE, 
1995] The following tables provide an overview of the most common 
antioxidants and their main function.  
Extracellular Antioxidants Mechanism 
Bilirubin Reaction with lipid-peroxyl- radicals 
Glutathione (GSH) non-enzymatic reduction of H2O2 and ONOO* 
Vitamin C Reduction of S-S-bonds 
Vitamin E Reaction with lipid-peroxyl- radicals 
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Albumin Binds Iron, reaction with OH* 
Transferrin Binds Iron  
Uric acid Binds Iron- and Copper 
Tab. 1: List of extracellular antioxidants (modified after MELCHER, 2010) 
Antioxidants Location Mechanism 
Primary 
Superoxide dismutase  
Catalase 
Glutathione-Peroxidase 
Glutathion (GSH) 
 
cytosol, mitochondria 
cytosol                   
cyotosol, mitochondria 
cyotosol, mitochondria 
 
O2* - dismutation 
H2O2 – reduction 
H2O2 – reduction 
substrate of GSH-Peroxidase 
secondary 
Bilirubin        
Glutathione-Reductase 
VitaminC             
Vitamin E 
 
cytosol 
cytosol 
membranes          
cytosol 
                               
reduction of S-S-bonds 
GSSG-reduction to GSH 
scavenges lipid- ROO*- radicals 
scavenges lipid- ROO*- radicals 
Tab. 2: List of primary and secondary antioxidants (modified after MELCHER, 2010) 
The main function of primary antioxidants is the detoxification of superoxide 
radical and hydrogen peroxide. Secondary antioxidants have the ability to stop 
radical chain-reactions (bilirubin, vitamin E), obtain the reduced state of primary 
antioxidants (Vitamin C, GSH-reductase), and stimulate the reduction of 
oxidized proteins. [HALLIWELL and GUTTERIDGE 1990, BLITZER 2002]  
2.1.3 Oxidative stress 
The term “oxidative stress” has been defined as an imbalance between 
oxidants, such as free radicals and antioxidants, due to an overload of 
prooxidants caused by low alimentary intake of antioxidants, degradation of 
endogenous antioxidants or a rise in reactive species, due to either mental or 
physical stress. Oxidative stress affects DNA, lipids and proteins as well as 
generates impairment and destruction of membranes, enzymes and eventually 
cell death. Free radical damage is able to accumulate and subsequently leads 
to cell damage.  Furthermore, it leads to diseases including cardiovascular 
diseases, atherosclerosis, diabetes, neurodegenerative and chronic diseases. 
[HALLIWELL, 1997] Various environmental and pathological factors trigger the 
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formation of oxidative stress such as radiation, ultraviolet radiation, atmospheric 
toxins, toxic chemicals and excess malnutrition. [DEVASAGAYAM et al., 2004] 
 
Fig. 1: Oxidative Stress (modified after ELMADFA and LEITZMANN, 2004) 
The influence of ROS in diseases was established by numerous studies, and 
presently over 70 pathologies are substantially connected with oxidative stress 
and its subsequent biochemical impact, such as peroxidation of lipids assessed 
by biomarkers including malondialdehyde (MDA) and 4-hydroxynonenal (4-
HNE), proteins evaluated by protein carbonyls, nucleic acids measured by 
oxidative DNA bases and carbohydrates determined by glycosilation products. 
[KUSANO and FERRARI, 2008] 
2.1.4 Lipid peroxidation 
Lipid peroxidation (LPO) is an extensively investigated mechanism responsible 
for cell aging and the development of diseases such as cardio vascular 
diseases (CVD) and cancer. Polyunsaturated fatty acids (PUFAs) are prone to 
peroxidation due to their instable structure that contains a number of double 
bonds which weaken the bond of the hydrogen atoms on the adjacent carbon 
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atom. The number of double bonds affects the susceptibility of PUFAs for 
peroxidation and therefore, parts are readily attacked by free radicals and 
become oxidized into lipid hydroperoxides. [PORTER et al., 1995] If the process 
is initiated, it continues as a free radical-mediated chain reaction. The 
termination of the reaction is affected by the oxygen concentration and the 
availability of antioxidants. The decomposition of hydroperoxides, which is 
activated by high temperatures and exposure to transition metal ions, leads to 
the production of secondary lipid peroxidation products including the aldehyde 
MDA and 4-HNE. Therefore, LPO products represent instable markers of 
oxidative stress with the tendency to form reactive byproducts. [GUTTERIDGE, 
1995] Lipid peroxidation markers such as MDA show elevated levels in the 
blood and plaques of atherosclerotic patients. [RAVANDI et al., 2011] 
2.1.4.1 MDA as a biomarker for oxidative stress 
Malondialdehyde is among the numerous reactive aldehydes, which derive from 
the decomposition of lipid peroxides, the most widely used biomarker for an 
overall lipid peroxidation. [KHOSCHSORUR et al., 2000]  
The method is based on the reaction of MDA with thiobarbituric acid (TBA), 
through which a MDA-TBA adduct is formed that can be assessed by 
fluorometry, spectrophotometry and high-performance liquid chromatography 
(HPLC). Due to a high reactivity with other substances such as bile pigments or 
other lipid peroxidation products, the specificity of this assay could be affected. 
However, it is a reliable method to test environmental and nutritional factors 
which are responsible for increased lipid peroxidation in a pathological as well 
as a healthy population. [WASOWICZ et al., 1993] Therefore, the TBA assay 
represents a simple and rapid way to determine lipid peroxidation in which MDA 
is derivatized, and it provides improved specificity due to HPLC-based methods 
in combination with fluorescence detection. [LYKKESFELDT, 2001] 
2.1.5 Methods to measure the oxidative capacity 
A method for the fast quantification of the capability of an antioxidant to prevent 
diseases is desirable. However, a total antioxidant capacity assay with only one 
chemical reaction is rather unlikely to provide an all-over outcome. Moreover, a 
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lack of a validated assays complicates the comparison of reported results from 
diverse research groups.  
Various researchers describe antioxidant capacity differently. [HUANG  et al., 
2005] The quantification of the antioxidant capacity includes the cumulative 
action of all antioxidants present in body fluids and plasma, and moreover, yield 
an integrated parameter rather than the simple amount of measurable 
antioxidants. A complete antioxidant capacity potentially provides more 
biologically relevant information than the determination of individual antioxidant 
concentrations. The antioxidant capacity of the cell is essentially due to the 
enzyme system, whereas that of plasma is mainly modulated by dietary 
antioxidants and therefore represents a more adequate example for the in vivo 
balance between oxidizing species and antioxidant substances. [GHISELLI  et 
al., 2000]  
The “antioxidant capacity” determined by a particular assay describes only the 
chemical reactivity in terms of specific conditions applied in the examination and 
therefore, the results cannot be generalized as reference to the “total 
antioxidant activity”. [HUANG et al., 2005]  
FRANKEL and MEYER [2000] suggested that one-dimensional methods to 
evaluate biological antioxidants are disadvantageous. To establish an 
appropriate method, the authors indicate that a test protocol ought to 
adequately (a) choose a biologically relevant substrate, (b) check various 
oxidation conditions, (c) measure initial as well as secondary oxidation 
products, (d) compare antioxidants at the identical molar concentrations of 
active substances and (e) quantify based on the percent inhibition, rates of 
hydroperoxide constitution or decomposition and the induction period.  
Standardized analytical methods of antioxidant capacity would provide an 
instruction for the adequate implementation of assays, validate the comparison 
of data, serve as an aid to control potential variation within or between 
compounds, and lastly, provide the allocation of quality standards for regulatory 
issues and health claims. [PRIOR et al., 2005] Therefore, PRIOR et al. [2005] 
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suggested a list of requirements for the standardization of antioxidant capacity 
assays for routine quality control analyses: (1) the detection of the chemistry 
effectively present in potential implementations, (2) the use of a biologically 
relevant radical source, (3) a simple appliance, (4) the employment of 
procedures with a defined chemical mechanism and endpoint, (5) an easy 
excess to the equipment, (6) adequate reproducibility, (7) applicable for the 
measurement of lipophilic as well as hydrophilic antioxidants and utilization of 
diverse radical sources and (8) the adaptability to high throughput analyses. 
To determine the total antioxidant capacity on the basis of a single method 
would provide insufficient data. Therefore, a multitude of different assays is 
required to assess the antioxidant status and oxidative stress appropriately 
including antioxidant capacity assays, the determination of isolated antioxidants 
and the utilization of biomarker for the measurement of oxidative stress 
damage. [PRIOR and CAO, 1999] 
2.1.5.1 Chemical backround 
Antioxidant capacity assays can be roughly subdivided into two major groups: 
methods with (a) reactions based on hydrogen atom transfer (HAT) and (b) 
reactions based on single electron transfer (SET). Both assays detect the 
radical or oxidant scavenging capacity, instead of the prophylactic antioxidant 
capacity of a sample. The HAT method quantifies the hydrogen atom donating 
capacity compared to the SET method, which measures the reducing capacity 
of an antioxidant. [HUANG et al., 2005] 
HAT-based assays consist of a synthetic free radical generator, an antioxidant 
and an oxidizable molecular sample and assess the competitive reaction 
kinetics, which leads to an evaluation deduced from the kinetic curves. [HUANG 
et al., 2005] HAT-based methods determine the ability of an antioxidant to 
quench free radicals by hydrogen (H) donation rapidly and independent of the 
pH-value. However, the presence of reducing molecules such as metals 
interferes with the reactivity. [PRIOR et al., 2005] 
AH + X*  A* + XH 
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The hydrogen atom transfer reaction represents a key step in the radical chain 
reaction and hence, HAT-based assays are more relevant to the assessment of 
unwanted lipid peroxidation in biological systems due to peroxyl radicals. 
Especially the ORAC assay provides useful information on radical chain-
breaking capacity as a result of the use of peroxyl radicals as the oxidant. 
Therefore, the ORAC assay presently presents the method of choice for 
quantifying the peroxyl radical scavenging capacity of samples. [HUANG et al., 
2005] 
Assays based on the HAT reaction include: [GÜLCIN, 2012] 
 Oxygen Radical Absorbance Capacity (ORAC) 
 Trolox equivalence antioxidant capacity assay (TEAC) 
 Inhibition of induced LDL oxidation 
 Total oxyradical scavenging capacity assay (TOSCA) 
 Crocin-bleaching assays 
 Chemiluminescent assay 
 
SET-based assays detect the capacity of a potential antioxidant to donate one 
electron and reduce compounds such as radicals, metal ions and carbonyl 
groups, which is expressed by a change in color. [HUANG et al., 2005] The 
relative reactivity correlates with the deprotonation and ionization potential of 
the reactive functional group.  [PRIOR et al., 2005] 
SET-based assays are composed of two elements in the reaction reagent: (a) 
the antioxidants and (b) the oxidant, which also represents the probe and 
absorbs an electron from the antioxidant and therefore, elicits a change in color 
of the sample.  
oxidant (probe) + e- (from the antioxidant)  reduced probe + oxidized antioxidant 
 
The intensity in the color change is proportional to the concentrations of the 
antioxidant, and when the color change reaches a plateau the end point of the 
10 
 
reaction has been achieved. An alternation of absorbance is plotted against the 
antioxidant concentration to provide a linear curve, which reflects the reducing 
capacity of the antioxidant, usually expressed in Trolox equivalence (TE). 
[HUANG et al., 2005] 
Various SET-based assays were developed to measure the reducing capacity 
of antioxidants at different pH-values, which influence the reaction (acidic, 
neutral and basic). Acidic conditions like the ones used in the FRAP assay, may 
suppress the reducing capacity based on protonation of antioxidant compounds. 
In basic conditions however, the reducing capacity of the probe would be 
enhanced due to proton dissociation of phenolic compounds. [HUANG et al., 
2005] 
The pH dependent procedure can be quite time consuming due to the slow 
completion of the reaction and measures the percentage reduction of the 
product instead of the kinetics. [PRIOR et al., 2005] The interference of 
contaminants such as metals possibly leads to a debased reproducibility and 
consistency of results. [HUANG et al., 2005] 
 
Assays based on the SET reaction include: [GÜLCIN, 2012] 
 Ferric ion reducing antioxidant power (FRAP) 
 Trolox equivalence antioxidant capacity assay (TEAC) 
 Total phenolics assay by Folin-Ciocalteu reagent assay 
 Total antioxidant potential assay (using a  Cu2+-complex as oxidant) 
 Cupric ions (Cu2+) reducing antioxidant power assay (PRAC) 
 2,2-Azinobis 3-etylbenzthiazoline-6-sulphonic acid radical scavenging  
assay(ABTS*+) 
 2,2-Diphenyl-1-picrylhydrazyl radical scavenging (DPPH*) 
 N,N-dimethyl-p-phenylenediamine radical scavenging assay (DMPD*+) 
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2.2 Bilirubin 
In 1849, VIRCHOW discovered bilirubin in blood extravasates and termed it as 
“Hematoidin”. In 1864, the name Bilirubin was given by STADELER, who 
obtained a defined and pure preparation of the dark red bile pigment and 
subsequently it was recognized that an accumulation of bilirubin was the reason 
of the yellow color in jaundiced patients. In 1874, TARCHANOFF showed the 
direct association between pile pigments and hemoglobin, and in 1942, 
FISCHER and PLIENINGER synthesized Bilirubin IXa and proposed a 
structure, which was accepted for over 30 years. [BOSMA, 2003] 
 
2.2.1 Structure 
All bile pigments share a similar structure skeleton, however each pigment 
possesses a characteristic ß-substituent. Bilirubin is a yellow colored bile 
pigment and exhibits a porphyrine structure, which consists of four covalent 
bound open-chain pyrrole rings. At the two pyrrolic rings on the outside are 
polar lactam groups (-CO-NH) bound in opposite to the inner pyrole rings, which 
are linked to polar propione sidechains (-COOH). The naturally found bilirubin 
IXa is a 4Z, 15Z isomer of the unconjugated form of bilirubin, which is formed by 
heme cleavage. [VITEK and OSTROW, 2009] 
 
 
Fig. 2: Structure of Bilirubin IXa [McDONAGH, 1997]  
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2.2.2 Heme catabolism 
Bilirubin, is the end product of heme catabolism and is derived from its 
metabolic precursor biliverdin in mammalian systems. [FARRARA et al., 1994] 
There are two forms of Bilirubin: direct reacting bilirubin, which is conjugated 
and found in the bile, as well as indirect reacting bilirubin, the unconjugated 
(UCB) main form in blood that only reacts in the presence of a catalyst. The 
direct form can be converted into the indirect form by glucuronidase, an enzyme 
that is involved in the degradation process of heme. [BOSMA, 2003] The 
bilirubin concentration in humans is based on the heme decomposition derived 
from hemoglobin and other hemoproteins including cytochromes, catalase and 
peroxidase, as well as a small pool of free heme. The production amounts to 
approximately 300mg per day, of which about 25% is produced from non-
hemoglobin sources and 75% of aged red blood cells. [VITEK and OSTROW, 
2009] 
Bilirubin is produced by the action of the enzyme heme oxygenase (HO), the 
rate-limiting enzyme in heme catabolism, that metabolizes cyclic heme into 
biliverdin, carbon monoxide and ferrous iron, followed by the reduction of 
biliverdin to bilirubin, catalyzed by biliverdin reductase. [VITEK, 2012]  
There are two catalytically active isoforms of heme oxygenase. HO-1 is in 
charge of reactions of acute phase instant response against oxidative stress. 
HO-2 is a constitutive isoenzyme, which is expressed mainly in the brain and is 
presumed to function as a neurotransmitter or neuromodulator. Furthermore,  a 
third enzyme (HO-3) exists, which is believed to have no coding function and is 
just represented by a pseudogene. [HAYASHI et al., 2004] However, a recent 
study showed possible regulatory functions of pseudogenes that might indicate 
HO-3 also has biological potential by contributing to gene regulation. [PINK et 
al., 2011] 
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Fig. 3: Bilirubin metabolism. The generation of bilirubin due to haeme-oxygenase and 
biliverdin reductase. [BOSMA, 2003] 
 
At the beginning of the metabolic process of bilirubin senescent or hemolyzed 
red blood cells degrade to hemoglobin, which is segmented to heme and globin. 
Heme is broken down to biliverdin IXa by oxidation, which in turn is reduced to 
bilirubin IXa and subsequently bound to the protein albumin, bilirubin is 
transported via bloodstream to the liver. [WILLIAMS et al., 2006] After reaching 
the liver, a basolateral organic-anion-transporter actively carries bilirubin in 
dissolved form in the cytoplasma by binding (itself) to specific binding proteins. 
Subsequently, two molecules of glucuronic acid react with UDP-
glucuronosyltransferase (UGT1A1) and conjugate bilirubin to bisglucuronosyl 
bilirubin, which is actively secreted into bile and further transported into 
intestinal lumen, where it is exposed to more metabolic changes. Moreover, 
14 
 
there are a number of crucial enzymatic steps essential for the homeostasis of 
bilirubin, which presumably influences the risk of metabolic diseases, such as 
cardiovascular diseases, diabetes, metabolic syndrome, arterial hypertension 
and obesity.  [VITEK, 2012]  
2.2.3 Physiological concentrations of bilirubin 
Many factors influence the serum bilirubin level, including gender, fasting, 
smoking, drug intake, race and age, which in turn affect the biological impact of 
bilirubin on the human body. [VITEK and SCHWERTNER, 2008] The average 
physiological concentration of bilirubin in healthy subjects ranges from 5-
17µmol/l. Considerably higher rates could be reached under diseased 
conditions, such as jaundice. [ASAD et al., 2001] Patients with GS exhibit a mild 
hyperbilirubinaemia with levels between 17,1 – 85µmol/l in contrast to the more 
severe variants, Crigler-Najjar (CN) 2 with 120 – 340µmol/l and CN1 with 340-
685µmol/l. [GILBERT and LEREBOULLET 1901, ARIAS 1962, CRIGLER 1952] 
2.2.4 Relevance of bilirubin as an antioxidant 
Antioxidants as well as toxic properties have been attributed to bilirubin [ASAD 
et al., 2001], and it was known for a long time to be a potentially toxic 
metabolite, especially for the central nervous system. Nevertheless, it might 
provide numerous beneficial effects for the human body, as data from the last 
few decades have proven [VITEK, 2012] Its antioxidant activity is predominantly 
due to its ability to disable free radical species such as peroxide radicals and 
superoxide anion. [ASAD et al., 2001]  
Due to the lipophilic nature of bilirubin, the molecule provides specific protective 
activity against lipid soluble metabolites. [STOCKER and AMES 1987, 
STOCKER 1990] Exogenous bilirubin has the ability to influence the lipid 
peroxidation in the heart and kidney and has a protective effect on thymus cells 
against apoptosis. [DUDNIK et al. 2001] Unconjugated as well as conjugated 
bilirubin safeguards low-density lipoprotein (LDL) against peroxidative attack of 
scavenging peroxyl radicals. [WU et al., 1996] 
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Bilirubin exhibits a constitution of conjugated double bonds in combination with 
a pair of reactive hydrogen atoms in all present forms including free, albumin-
bound and conjugated bilirubin. The reactive atoms dispense a hydrogen (H), 
especially to lipid-peroxyl radicals (LOO*) and subsequently form lipid 
hydroperoxide (LOOH) and bilirubin radicals. Due to the structure of bilirubin, 
the molecule is prepared to donate electrons to plasma oxidants to form its C-
10 methylene group. Therefore albumin-bound bilirubin has a major influence 
on the antioxidant activity in plasma and protects LDL particles from plasma 
oxidants. [STOCKER, 2004] In contrast to free bilirubin, the albumin-bound 
molecule forms oxidized biliverdin, which is reduced by the potent redox cycle 
of biliverdin reductase. [NEUZIL and STOCKER, 1994, BARANO et al., 2002]  
Moreover, bilirubin has been proven to be more effective at protecting lipids 
from oxidation than water-soluble antioxidants, like glutathione, with its main 
function of protecting proteins from oxidative damage. [SEDLAK et al., 2009] A 
study confirmed the cytoprotective effect of bilirubin in the brain, more 
specifically, the combination of bilirubin and GSH have complimentary 
cytoprotective qualities. Bilirubin accounts for the prevention of lipid 
peroxidation and could therefore be of great importance for the stability of 
membrane proteins due to their hydrophobic environment whereas GSH mainly 
protects against the oxidation of water-soluble proteins, hence diverse 
substances in the cytosol. GSH is able to protect against lipid peroxidation as 
well, with an excessively smaller potency of preventing oxidative degradation of 
lipids than bilirubin. [SEDLAK et al., 2009] Free radical mediated cell lysis is 
inhibited at significantly lower bilirubin concentrations, much more than other 
potent antioxidants including ascorbate or Trolox. [ASAD et al., 2001] A minimal 
level of bilirubin (10µM) is able to protect against 10000 times higher 
concentrations of hydrogen peroxide. [DORE et al., 1999] Compared to the 
vitamin E analog Trolox, a lipid-soluble antioxidant, bilirubin has been shown to 
be nearly 30 times more effective in preventing in vitro LDL oxidation. [WU et 
al., 1994] Furthermore, serum bilirubin has been indicated to be a considerable 
contributor to the total antioxidant capacity in blood. [FREI et al., 1988]  Bilirubin 
has also been demonstrated to have anti-inflammatory properties. [VITEK and 
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SCHWERTNER, 2008] Therefore, among other functions, bilirubin is able to 
scavenge overproduced reactive oxygen species, activate anti-inflammatory 
actions and has direct effects upon cell signaling. [VITEK et al., 2007a]   
2.3 Inherited forms of unconjugated hyperbilirubinemia 
There are three grades of inherited unconjugated hyperbilirubinemia known in 
the human body, which all show a normal morphological liver and other hepatic 
functions that are unaffected, as well. 
2.3.1 Morbus Gilbert  
The least severe form, Gilbert syndrome, was first introduced in 1901, by 
GILBERT and LEREBOULET. [1901] It is the most common hereditary cause of 
increased bilirubin. This condition is found in 3 – 10 % of the general population,  
with a more frequent occurrence in males (12,4%) than in females (4,8%). 
[RADU & ATSMON, 2001] A harmless jaundice caused by elevated levels of 
unconjugated bilirubin in the bloodstream is the main symptom and requires no 
treatment. It is characterized by unconjugated hyperbilirubinemia that occurs in 
the absence of bilirubinuria, hemolytic anemia or liver malfunction. 
[SAMPIETRO et al., 1999] Gilbert syndrome does not lead to chronic liver 
dysfunction or fibrosis and is therefore considered benign. 
GS is characterized by a decrease in hepatic bilirubin UDPGT activity (>50%) 
and describes a heterogeneous group of disorders. [FELSHER BF, 1973] 
Although a congenital defect, GS seldomly becomes clinically apparent until 
after puberty due to hormonal (steroids) suppression of the hepatic bilirubin 
clearance. [ODELL, 1980] The disorder is based on a reduction in bilirubin 
glucuronidation catalyzed by the UDP-glucuronosyltransferase (UGT1A1). 
[BOSMA et al. 1995, BOSMA 2003] Due to diminished activity of the 
conjugation enzyme, which is solely responsible for bilirubin glucuronidation, the 
conjugation of bilirubin is reduced, which is associated with an enhanced 
production of monoconjugated bilirubin. [DELGIUDICE et al., 1999] 
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Fig. 4: Ribbon diagram of the predicted 3D structure of UGT1A1. The purple ribbons are 
α-helices, and the long arrow indicates the β-sheet. In codon 71 in the α-helix of the 
mutated UGT1A1, the dotted arrow indicates the replacement of arginine for glycine. 
[LEE et al., 2010] 
BOSMA et al. [1995] and MONAGHAN et al. [1996] proved a polymorphism in 
the promoter region of the gene for UDPGT1 which seemed to occur in most 
patients with Gilbert Syndrome. The UGT1A1 gene and its TATA box, a 
phenoborbital responsive enhancer module in its regulatory region, [RITTER  at 
al., 1992] is determined on chromosome 2q37 and encodes nine functional 
proteins. [URAWA et al., 2006] 
The wild type of TATA box exhibits six recurrences of TA and is conventionally 
written as A(TA)6TAA. [RITTER et al., 1992] In subjects with Gilbert Syndrome, 
a variant promoter for the gene encoding bilirubin UDP-glucuronosyltransferase 
(UDPGT) contains a two-base-pair addition (TA) in the TATAA unit, upstream of 
the first exon of UGT1A1, showing seven rather than the usual six repeats. 
[BOSMA et al., 1995] The additional dinucleotide has been indicated to 
decrease the expression of the UDPGT1 gene, and the bilirubin conjugation in 
Gilbert Syndrome is the result. This leads to a 70 to 80% reduction of bilirubin 
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glucuronidation in homozygous UGT1A1*28 carriers. [BOSMA et al. 1995, 
BOSMA 2003] 
 
Fig. 5: Nucleotide sequence of the BGT gene promoter. [TRIOCHE et al., 1999] 
Between the length of the TATAA element and UGT1A1 expression, an inverse 
correlation was detected. The homozygosis for the variant TATAA element 
alone is not sufficient for the manifestation of the Gilbert phenotype, and other 
factors also contribute to the serum bilirubin levels. [BOSMA et al. 1995] This 
phenotype is for instance seen less often in women, most likely due to the lower 
daily bilirubin production. [KADAKOL et al., 2001] 
2.3.1.1   GS in ethnic groups 
Between different populations a discrepancy of the genetic background of GS 
occurs. Clinical GS in Caucasians is characterized by a reduced UCT1A 
transcription caused by A(TA)7TAA polymorphism with a frequency of the 
UGT1A1*28 allele between 35 and 40%. [BOSMA et al., 1995] Hence, the 
homozygous mutation occurs in 11-16% of the cases. [MONAGHAN et al., 
1996] The majority of Caucasians and Africans with Gilbert Syndrome has a 
homozygous TA insertion in the promoter region of the UGT1A1 gene, which is 
believed to be the main cause of this condition. Though less common in people 
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of an African origin, two additional polymorphisms of the TATAA unit have been 
observed, a shorter sequence A(TA)5TAA of the UGT1A1*36 gene and a longer 
sequence A(TA)8TAA of the UGT1A1*37 gene, which leads to increased 
transcriptional activity. [EHMER et al., 2008] Some populations show a minor 
commonness for the UGT1A1*28 allele and therefore develop other mutations 
causing GS. [HALL et al., 1999] The phenotype G71R allele, which was not 
found among a European population, commonly occurs in Japanese and Asian 
individuals, more specifically in jaundiced newborns. Due to a homozygous and 
heterozygous G71R mutation the expression of bilirubin UGT is 40-70% 
decreased. [YAMAMOTO et al., 1998] Furthermore, among an Asian 
population, elevated serum bilirubin levels where detected, elicited by the 
Y486D mutation, although the frequency of the G71R and Y486D alleles 
containing these mutations are unknown. [SATO et al., 1996] 
2.3.1.2 GS in neonates 
Physiological neonatal jaundice manifests during the first 5 days of life, in about 
50% of neonates and primarily occurs from unconjugated bilirubin. 
[CHOWDHURY et al., 1995] A delayed maturation of bilirubin uridine 
diphospate-glucuronosyltransferase (UGT1A1) reduced erythrocyte lifespan, 
but an increased load of bilirubin to the liver trigger elevated bilirubin levels in 
newborns. Breast-fed infants develop a higher plasma bilirubin level of 256-
410µmol/L in the space of the first 10-19 days. [OSBORN et al., 1984] 
GS is speculated to influence the development of neonatal hyperbilirubinemia, 
which is defined by an increased total bilirubin plasma level above 223µMol/L. 
[MAISELS, 1988] Many incidences of GS occur in neonates and are suggested 
to amplify the development of neonatal jaundice within the first 2 days of life. 
[BANCROFT et al. 1998] KAPLAN et al. [1997] demonstrated that neonates 
with a G-6-PD-deficiency in combination with the variant UDPGT1 promoter 
have a higher risk to develop hyperbilirubinemia. If just one condition is present, 
the G-6-PD-deficiency or the presence of the variant allele alone did not raise 
the risk of hyperbilirubinemia.  
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The risk for neonates to develop a serious hyperbilirubinemia is highly 
dependent on the serum bilirubin level at discharge. Nevertheless, of the 
discharged newborns with an increased risk, only approximately 8% develop a 
major hyperbilirubinemia. [KEREN et al., 2008] The combination of clinical and 
laboratory data are needed to identify infants with an affinity for elevated 
bilirubin levels. [HANCHARD et al., 2011] 
For European, North American and African infants with a prolonged neonatal 
jaundice, BURCHELL and HUME [1999] advise a genetic screening test for GS 
detecting a possible TATA box mutation of UGT1AA. In Japanese neonates, the 
Gly71 Arg mutation should be determined.   
2.3.1.3 Symptoms and Treatment 
Gilbert’s syndrome is a benign condition causing mild, unconjugated 
hyperbilirubinemia manifested by episodes of mild intermittent jaundice and an 
absence of overt hemolysis or liver disease. [WATSON and GOLLAN, 1989] 
The morbidity and mortality are not significantly affected, and no major 
dysfunctions of the drug metabolism were detected. However, the risk of drug 
toxicity may be increased due to concurrent genetic deficiencies in xenobiotic 
pathways. [DeMORAIS et al. 1992] Thus, a clinical screening for GS is advised 
despite the non-existence of a specific treatment. [BOSMA, 2003]  A recent 
study suggests that GS might pose a potential risk factor for drug toxicity. As a 
common condition in GS, a haplotype of multiple genetic variants at the UGT1A 
gene locus changes the responsiveness and the expression of a human 
UGT1A1 significantly. Moreover, the study redefined the functional and 
molecular basis of GS as a condition with a complex genotype and is possibly 
able to modify the metabolism extensively and is therefore, a potential risk 
factor for infection and drug therapy. [EHMER et al., 2012] 
In another study, GS probably influences the prevalence of cholelithiasis and 
might exhibit a higher possibility for gallstones at a relatively young age. 
[ORIGA et al., 2009] 
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ASTOFLI et al. [2011] investigated the relation between GS and breast cancer. 
The affected function of the UGT1A1 enzyme of GS patients causes a level of 
degradation of 4-OH-estrogens, which represent estrogen metabolites and acts 
cancerogenous. It is suggested that the risk for breast cancer rises because of 
the polymorphism UGT1A1*28 in GS subjects as well as a potential exposure to 
increased exogenous hormones. To date, no studies exist that compare the 
level of jaundice in breast cancer patients to healthy individuals, and relations 
between GS and breast cancer are insufficiently evaluated. Therefore, the 
correlation between GS and breast cancer is simply a theory and needs to be 
affirmed by further clinical studies. 
2.3.1.4 Methods to diagnose GS 
2.3.1.4.1 The “caloric restriction” or “starving test” 
This procedure was developed by Agustine Gilbert in 1906, and is characterized 
by two days of fasting (max. 400kcal per day) and a subsequent elevation of 
unconjugated serum bilirubin up to 100 %. A distinct difference between GS and 
healthy individuals should be given, though the discrimination was insufficient if 
patients with acute hepatitis or liver cirrhosis were compared to GS subjects. 
[THOMSEN et al., 1989] The caloric restriction test requires a hospital 
admission during the 2-day testing phase to monitor the caloric intake and the 
blood glucose levels and is for this reason extremely time consuming. [TEICH et 
al., 2008] 
2.3.1.4.2 The nicotinic acid provocation test 
GS can be diagnose if a mild, fluctuating unconjugated hyperbilirubinemia is 
present without persisting hemolysis, and a regular outcome of other liver 
function tests is performed. After an overnight fast, an intravenous (50mg) or 
oral (170-300mg) administration of nicotinic acid (niacin) induces an increase of 
unconjugated serum bilirubin, which is subsequently measured every 30-60 
minutes for about 5 hours. GS Subjects show a more potent rise and a delayed 
clearance in comparison to healthy individuals. [FROMKE and MILLER, 1972] 
Due to the positive outcome for individuals with GS and chronic liver disease, 
the nicotinic acid test does not qualify for a differentiation between those 2 
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groups. [DICKEY et al.,  1991] In other studies, both the nicotinic acid test and 
the starving test were compared and reported a more potent increase of 
bilirubin in the former method. [DAVIDSON et al., 1975] 
2.3.1.4.3 Overnight Rifampin Test 
The Rifampin Test is a highly sensitive and specific procedure. The substance 
competes for the excretory pathways in liver cells and further induces 
cytochrome P-450 isoenzymes. [HALLAL et al., 2006] An oral dose of 900g 
Rifampin is given to both fasting as well as nonfasting adults, which causes a 
much higher rise of total serum bilirubin in GS patients than in healthy subjects. 
After fasting and the subsequent oral application, the bilirubin concentration 
increases > 1,9 mg/dl after 2-6 hours. Without fasting, the level rises > 1,5 mg/dl 
after 4-6 hours. Due to the extreme increase in GS in comparison to healthy 
individuals, the method is able to differentiate between these two groups.  
[MURTHY et al., 2001] A rise of serum bilirubin > 2,4mg/dl provides a 93,8% 
sensitivity and 93% specificity compared to the increase of unconjugated 
bilirubin > 1,3mg/dl with 100% sensitivity and specificity for the diagnosis of GS. 
Hence, the method represents a useful diagnosis of GS if those cut-off levels 
are used. [MOUSAVI et al., 2005] THALLAL et al. and MURTHY et al. did not 
report possible adverse effects such as heartburn, vomiting or hepatitis due to  
Rifampin, which may induce hemolysis. Additionally, severe hypersensitivity 
reactions including the Stevens-Johnson Syndrome, toxic epidermal necrolysis 
and intravascular coagulation, which represent more serious complications and 
seldomly occur after the administration of Rifampin, were documented. [TEICH 
et al., 2008] 
2.3.1.4.4 Fractionation via thin-layer chromatoghraphy 
In the diagnosis of GS, the following method provides an exact measurement of 
conjugated and unconjugated bilirubin levels. In GS, approximately 6% of the 
total serum bilirubin is conjugated, compared to the higher amount of 17% in 
healthy subjects and 28% in patients with chronic hepatitis. For this particular 
method fasting is not required because it does not affect the percentage of 
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conjugated bilirubin, despite an increased total serum bilirubin level. [SIEG et 
al., 1990] 
2.3.1.4.5 Genetic testing 
Genetic testing is a valuable method, especially for the investigation of 
prolonged jaundice in neonatals. GS is an important criterion to detect a 
prolonged neonatal jaundice because of its contribution to hyperbilirubinemia. 
[LAFORGIA et al. 2002] Furthermore, for standard therapy with certain drugs 
(Atazanavir and Irinotecan), the genotyping for the (TA)7 variant of the UGT1A1 
promoter region is more commonly used as a predictive factor. The gold 
standard method for genotyping the UGT1A1*28 mutation is characterized by 
the time-consuming direct sequencing of the UGT1A1 promoter region. 
[EHMER et al., 2008]  
2.3.2 Crigler-Najjar-Syndrom 
Two additional and more severe variations of pathologic hyperbilirubinemia 
were named after their discoverers, Crigler and Najjar, and are autosomal 
recessive disorders. [ARIAS, 1962] 
Type I described first by CRIGLER and NAJJAR in 1952, is a rare form with 
approximately 170 described cases worldwide until 1999. [JANSEN, 1999] It 
represents an acute form of indirect hyperbilirubinemia with increased bilirubin 
levels of 15-50mg/dl and tends to result in death within the first few months in 
infants. This form is characterized through the nearly complete absence of 
UDP-glucuronosyltransferase and the significantly low enzyme activity below 
1%. [CRIGLER and NAJJAR, 1952] The therapy includes phototherapy, blood 
transfusions, plasmapheresis and liver transplantation. [FOX et al., 1998] A 
study with gunn-rats investigated the phenotype of Crigler-Najjar (CN) I to 
develop a new approach of therapy. Instead of observing liver cells, which 
seldomly multiply, fibroblasts are used as a unit of measure for the transfection 
in combination with UDP-glucuronosyltransferase and were subsequently 
implanted in rats. After the completion of the procedure, the bilirubin level 
decreased to the standard value of healthy subjects. However, after 6 weeks all 
rats developed peritoneal tumors. [SEPPEN et al., 1997] 
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In 1962, the less lethal type CN II was distinguished from type I and 
subsequently described by ARIAS  and CRIGLER. The serum bilirubin level of 
type II patients is elevated to 10-20mg/dl, and the enzyme activity is determined 
at 1-10%, which represents an indirect hyperbilirubinemia. For a differential 
diagnosis of type I and Type II, Phenobarbital can be administrated, which 
induces an enzyme induction of the UDP-glucuronosyltransferase and yields a 
30% decrease of the bilirubin level in type II. [ARIAS, 1962] 
2.3.3 GS and Cardiovascular diseases  
CVD are the main source for death in developed countries and include 
atherosclerosis, coronary heart disease, stroke and hypertension. 
Atherosclerosis is characterized by a thickening and stiffening of arteries due to 
fatty plaques and mineral accumulation, which leads to an insufficient supply of 
blood in the myocardium.  [RAVANI et al., 2011] Cardiovascular tissue injury 
has been suggested to be a result of oxidative stress in cardiac and vascular 
myocytes. [DHALLA et al., 2000] Furthermore, a significant deposit of iron in 
atherosclerotic lesions indicates that the iron catalyzed formation of free 
radicals possibly influence the development process of atherosclerosis. [YUAN  
and LI, 2003] 
A negative association between the prevalence of CVD and an elevated 
circulation of bilirubin was shown in a number of studies. [VITEK et al., 2002 
and LIN et. al, 2006] Moreover, a negative link and dose-response between 
serum bilirubin and the atherosclerotic process in humans is speculated. 
[NOVOTNY and VITEK, 2002] A strong association with a decreased risk of 
CVD is exhibited by homozygous UGT1A1*28 allele carriers with high serum 
bilirubin concentrations. [Lin et al., 2006]  
GS patients have a minor susceptibility of serum oxidation, regulated by the 
relationship between the oxidizability of serum and the serum bilirubin 
concentration, which possibly indicates a potential mechanism for the 
diminished prevalence of CVD in GS. [BLUMER et al., 2008] CVD exhibit 
increased oxidation of circulating lipids related to a liability of plasma to copper 
afflicted oxidation. Furthermore, CVD and hyperlipidemia patients have an 
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elevated rate of plasma oxidation, due to the lower concentrations of lipophillic 
antioxidants. [KONTUSH et al.,1997]  
BLUMER et al. reported a beneficial lipid profile in GS patients due to a higher 
ratio of HDL:LDL in plasma compared to a healthy group, independent of the 
physical activity level and alimentary intake of saturated fat. A difference of 
13,3µmol/l in circulating bilirubin between GS and healthy subjects, which yields 
to a 13,6% amelioration in the liability of plasma to oxidation was presented. 
[BLUMER et al., 2008]  
A study showed a significantly lower spectrum of atherogenic lipoprotein in 
patients with GS, due to a negative correlation between unconjugated bilirubin 
and small dense LDL as well as triacylglycerides. This inverse relationship 
constituted an approximately three times lower presence of atherogenic 
lipoprotein spectrum in GS subjects than in the healthy control group. 
Therefore, individuals with GS may have a decreased risk of atherosclerosis 
because of the amplifying effect of reduced small dense LDL levels on the 
protective antiatherogenic effect of hyperbilirubinemia. [OCADLIK et al., 2011]  
A population study revealed a significantly reduced risk for the development of 
CVD given that the bilirubin level was increased by 17µmol/l. [HOPKINS et al., 
1996] In a group of 15,000 men, the correlation between CVD and bilirubin 
indicated that each 1,0µmol/l increase in serum bilirubin diminished the potential 
CVD risk approximately 6,5%. [NOVOTNY and VITEK, 2003] With 2%, male 
patients with GS show a significantly decreased prevalence of ischemic heart 
disease compared to healthy individuals with approximately 12%. [VITEK et al., 
2002] 
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3 Materials and Methods 
 
3.1 Study design 
This current study aims to establish the genotoxic effect of Billirubin regarding 
subjects with GS compared to a healthy control group. The main objective is to 
identify affected metabolites, which are associated with GS and in addition, to 
also generate hypotheses for further investigations. This research was 
conducted as a part of the project entitled “The physiological relevance of bile 
pigments”, (FWF Austrian Science Fund; project no. P21162), which was 
executed at the Department of Nutritional Sciences, University of Vienna.  
3.1.1 Required criteria for subjects 
 
Inclusion criteria: 
 age 20 – 80 years 
 activity of y-glutamyltranspeptidase < 100 IU 
 activity of alanine-aminotransferase < 100 IU 
 activity of aspartate-aminotransferase < 100 IU 
Subjects with GS: 
 total serum bilirubin concentration > 20.52 µmol/L (>1.2 mg/dl) 
 unconjugated serum bilirubin concentration > 17.1 µmol/L (>1 mg/dl) 
Healthy control subjects: 
 total serum bilirubin concentration < 20.52 µmol/L (<1.2 mg/dl) 
 unconjugated serum bilirubin concentration < 17.1 µmol/L (<1 mg/dl) 
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Exclusion criteria: 
 younger than 20 and older than 80 years 
 currently smoking > one cigarette per day 
 alcohol consumption > 7 beverages per week 
 excessive exercise > 10 hours per week 
 medication that affects the liver metabolism (e.g. Rifampicin, Probenecid) 
 antioxidant supplementation in the past 4 weeks prior the blood sampling 
 a history of diseases like cardiovascular diseases, liver diseases (e.g. 
hepatitis B or C), haemolysis, cholelithiasis, cancer (past or present), 
chronic kidney diseases and diabetes mellitus 
 persons with transplants 
 
3.1.2 Classification of the participants 
 
 
Fig. 6: Classification of participants 
Total 
Participants 
n= 100 
GS    
Group 
n= 38 
Control 
Group 
n= 38 
Excluded 
Participants 
n= 24 
GS       
Male  
n= 28 
GS   
Female 
n= 10 
Control 
Male 
n= 28 
 
Control 
Female 
n= 10 
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3.1.3 Subject recruitment 
Subjects were recruited by newspaper, Internet advertisements and postings on 
notice boards of public establishments (universities, hospitals, pharmacies), as 
well as by clinical staff of the General hospital of Vienna. All chosen participants 
who met the inclusion criteria, have given their informed written consent.  A total 
number of 104 subjects was recruited, out of which 76 fulfilled the required 
inclusion criteria and were allocated into a GS group (n= 38) or a control group. 
(n= 38) 
The participants had to keep 2 appointments in order to complete the study. On 
the first appointed day, potential subjects had to provide a small blood sample 
and complete a questionnaire. Subjects who met the inclusion criteria were then 
invited for a second examination day. On the day preceding the second 
examination the subjects were supposed to maintain a low caloric diet with 400 
kcal in total until 5 p.m., followed by an overnight fast. On the following morning, 
venous blood was sampled by trained medical staff at the General hospital of 
Vienna. Furthermore, cell samples from both the buccal mucosa and urine were 
taken. 
3.1.4 Blood preparation 
Blood samples were taken from test persons and collected in tubes containing 
ethylene-diamin-etetraacetic-acid (EDTA) or Heparin. Afterwards, the samples 
were centrifuged at 4°C and 2400g for ten minutes. The serum was separated 
and stored for further use at -80°C. 
 
 
 
 
 
29 
 
 
3.2 ORAC – Oxygen Radical Absorbance Capacity 
The Oxygen Radical Absorbance Capacity Assay is a widely accepted standard 
tool for the measurement of antioxidative activity in the nutraceutical, 
pharmaceutical and food industries.  [HUANG et al., 2002b] It is a relatively 
simple method, though sensitive and reliable of quantitating the oxygen radical 
absorbing capacity (ORAC) of antioxidants in human serum. [CAO et al., 1993] 
HUANG et al. [2002b and 2002a] adjusted the method to a fully automated 
high-throughput system with a microplate fluorescence reader in a 96-well 
dimension and modified the procedure to further permit the identification of the 
lipophilic, hydrophilic and total antioxidant capacity of a compound. The peroxyl 
radical generater 2,2’-azobis 2-amidinopropane dihydrochloride (AAPH) was 
applied for measuring the “total antioxidant capacity” of hydrophilic and 
lipophylic substances in protein free plasma. [PRIOR  et al., 2003] Due to the 
standardization of the ORAC assay in combination with the use of a common 
calibrator, the method can be performed on many different compounds and 
foods. This allowed the formation of a database for an easy comparison of 
antioxidative capabilities of many different materials. [WU et al., 2004] 
3.2.1 The Principle of ORAC 
The ORAC assay is based on the oxidation of a fluorescent sample of peroxyl 
radicals through a hydrogen atom transfer process.  The Assay is based on the 
inhibition of peroxyl-radical-induced oxidation and initiated by thermal 
decomposition of azo-compounds (AAPH). [PRIOR et al., 2003] AAPH 
generates molecular nitrogen and two carbon radicals.  It can cause either a 
stable compound, or in combination with molecular oxygen, it can cause peroxyl 
radicals. [OU et al., 2001] These radicals decrease the intensity of the colored 
fluorescein and can be measured fluorimetric. If the radical generator is 
confronted with antioxidants, depending on their antioxidant capacity, they 
absorb the present peroxyl radicals and the decrease of the pigment intensity is 
decelerated. [PRIOR et al., 2003] The sample antioxidant capacity correlates to 
the fluorescence decay curve and is described as area under the curve (AUC), 
which is used to quantify the total peroxyl radical antioxidant activity in a 
sample. To compare the water-soluble vitamin E analog Trolox is used for the 
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antioxidant standard curve. [OU et al. 2001, HUANG et al. 2002b] ORAC is the 
only method that provides a complete assessment in which the inhibition time 
and inhibition degree is combined into a single quantity as the reaction goes to 
completion. [OU et al., 2001] 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: Principle of the ORAC assay [HUANG et al., 2002b] 
 
The ORAC assay according to HUANG et al. [2002b] and PRIOR et al. [2003] 
was priviously adjusted to FLUOstar Optima, a microplate fluorescence reader 
with a 96-well format at our department. [STADLMAYER, 2009] Our research is 
based on this altered procedure with further modifications including the use of a 
lower dilution factor (1:160 instedt of 1:620) and half of the amount of AAPH 
and buffer solution (426,42mg dissolved in 5ml buffer, heated to 37°C). 
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3.2.2 Reagents and Instruments 
Reagents Chemical 
Formula 
Manufacturer 
Fluorescein disodium salt 
Trolox®                                                
(6-hydroy-2,5,7,8-tetramethylchroman-
2-carboxylic acid) 
Phosphate buffer (pH 7,4) 
C20H10Na2O5 
                  
C14H18O4 
                 
Na2HPO4 
 
 
Fluka Chemica 
(CH) 
2,2’-Azobis                                                   
(2-amindinopropane)dihydrochloride 
(AAPH) 
C8H18N6 * 2 HCl 
 
Aldrich (D) 
Apparatus Manufacturer 
FL 600 Microplate Fluorescence 
Reader: FLUOstar Optima 
 
Bio-Tek Instruments 
96-well black polystyrene microplates Greiner Bio-one Ltd. (D) 
Pipettes  
(500µl, 1000µl,1200µl, 5000µl) 
 
Eppendorf 
Tab. 3: Reagents and Instruments for the ORAC test 
 
Phosphate buffer 75mmol/L, pH 7,4: In 1 L bi-distilled H2O, there was 10,96g 
Na2HPO4 and 10,21g KH2PO4 dissolved. Due to the pH sensitivity of 
fluorescein, the pH was adjusted to 7,4 with KOH. The pH-value is important for 
the function of fluorescein. 
 
AAPH Solution (97%): 426,42mg AAPH was dissolved shortly before measuring 
into 5ml preheated (37°C) phosphate buffer, to provide a concentration of 315 
mmol/L.  
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Fluorescein disodium stock solution: For a concentration of 4,19*10-3, 0.158mg 
fluorescein disodium was dissolved in 100ml phosphate buffer. 
 
Fluorescein disodium working solution: To obtain a final concentration of 
8,16*10-5mmol/l 487,5µl of fluorescein disodium, stock solution was dissolved 
into 25ml phosphate buffer. The amount was sufficient for 4 measurements. 
 
Trolox® (Standard): For the stock solution 62,58mg of Trolox was mixed with 
100ml of PBS buffer for a concentration of 2500µmol/l and placed in an 
ultrasonic bath until completely dissolved. 500µl of the Trolox stock solution was 
filled in cups and frozen at -80°C for further use.  To establish a standard line 
the solution was diluted to concentrations of 6.25, 12.5, 50, 75 and 100µmol/l. 
 
Sample Plasma: Before analyzing, the samples were defrosted, centrifuged and 
diluted with phosphate buffer at the ratio of 1:160. 
 
Reference Plasma (Control): To ensure accurate performance, the same 
plasma from a healthy female subject was used for every measurement and 
prepared exactly the same way as the plasma sample (dilution factor 1:160). 
 
The Phosphate buffer, Fluorescein, and the Standard solution were prepared in 
advance, filled in opaque bottles and kept at 4°C. The Trolox® standard 
solution, the AAPH solution and the fluorescein working solution were made 
daily and secured properly to protect from daylight. 
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3.2.3 Instrument settings 
 
Test name ORAC 
Mode Fluorescence, Plate Mode 
Microplate Greiner black 96-well 
No of cycles 35 
No of flashes per well and cycle 10 
Cycle time 60 
Filter and Integration Extinctions filter: 485nm 
Emissions filter:  520nm 
Incubation On, 37°C 
Shaking options Orbital, 1s, before first cycle 
Gain Adjusted automatically 
Tab. 4: Basic Instrument settings ORAC 
 
 
First, the FLUOstar Optima had to be activated, the appropriate settings 
adjusted and the incubation enabled (37°C). The instrument is able to measure 
absorbance as well as fluorescence with different measurement adapters. 
Therefore, it is of the utmost importance to check if the correct one is used. 5ml 
of phosphate buffer was kept in a 37°C warm water bath, and 426,42mg AAPH 
was provided for later use. Six solutions were prepared for the standard curve 
from 6,25 to 100µmol/l. The plasma was diluted with phosphate buffer in test 
tubes in a ratio of 1:160 and vortexed. After finishing the solutions, the reagents 
were transferred into the wells of the microplate with electronic Eppendorf 
pipettes based on the schemata in table 5. 
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Reagents / well Blank (µl) Control (µl) Standard (µl) Sample (µl) 
Phosphate buffer 25    
Trolox®  25   
Sample Plasma   25  
Reference Plasma    25 
Fluorescein solution 150 150 150 150 
Incubation of the microplate for 10 minutes at 37°C in FLUOstar Optima 
AAPH solution 37°C 25 25 25 25 
Tab. 5: Pipetting schemata (max. volume 350µl/well) for ORAC 
 
The blank, standards, controls and samples were analyzed in duplicate via 
electronic Eppendorf pipette. All steps of the schemata were followed, 
beginning with 25µl blank in each well of column 1A to 1B. 25µl of control 
plasma/well was pipetted in column 1C to 1F. The standard solutions were 
transferred in column 1G to 2G, beginning with 6,25µmol up to 100µmol. In 
columns 3A to 6H, each plasma sample was inserted twofold. In every well 
150µl fluorescein working solution was added, and the half filled microplate was 
immediately inserted into the FLUOstar Optima. Without measuring, a test 
program was adjusted to incubate for 10 minutes at 37°C and shaken for 3 
minutes. After the incubation, the recently dissolved AAPH that was preheated 
in the phosphate buffer was transferred into each well (25µl). The plate was 
reloaded into the microplate reader, and the fluorescence was measured every 
minute for 35 minutes in adjusted conditions (pH 7.4, 37°C). An 
evaluationsoftware collected the data points during this period, compared them 
with the data of the standard (Trolox) and expressed them as µmol of Trolox 
equivalents TE/1. The calculation of the data is described in section 1.4. 
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Plate 1A 
 
B…Blank, C…Control (reference plasma), T…Trolox, S…Sample plasma 
Tab. 6: First half of Microplate for ORAC 
 
Plate 2A 
 
B…Blank, C…Control (reference plasma), T…Trolox, S…Sample plasma 
Tab. 7: Second half of Microplate for ORAC 
 
3.2.4 Work plan for the ORAC assay 
In order to maintain the total analyzing time of 35 minutes, 6 columns were filled 
per run (half a plate). The columns were first incubated for 10 minutes, 
thereafter the AAPH solution was added and measured for a further 35 minutes. 
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For ideal timing, two microplates were used simultaneously. When the first plate 
was measured, the 6 first columns of a second one were then prepared. When 
the first half of the second plate was in the reader, the second half of the first 
plate was arranged. Each plate was completely filled, though only used once. 
 
3.2.5  Processing of data 
By applying the formula of the area under the curve into a Microsoft Excel 
spreadsheet, the data were analyzed. By subtracting the AUC of the blank from 
that of the sample, the Net AUC was obtained. [OU et al., 2001] 
 
a. Calculation of the AUC and the Net AUC for samples (plasma) and 
standard (Trolox) 
 
 
 
 
Fig. 8: Illustration of Net AUC (ORAC) 
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a. Standard curve 
The curve was obtained by plotting the concentrations 6.25, 12.5, 50, 75 and 
100 [µmol/l] of Trolox against the corresponding Net AUC. 
 
 
 
Fig. 9: Linear plot of Trolox concentrations vs. the Net AUCs 
 
b. Calculation of ORAC values via Trolox regression equation 
The relative ORAC value (Trolox equivalents) was calculated and expressed 
as µmol Trolox equivalent/l and the dilution factor of the plasma (1:160) was 
taken into account. 
 
ORAC value = 
[(AUCsample - AUCblank)/(AUCtrolox - AUCblank)] x (molarity of trolox) 
 
3.2.6 Quality assurance 
Over a period of two days, reference plasma was determined twofold. The table 
below shows the standard deviation (SD) and the coefficient of variation for 
intra- and interday. 
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 Orac 
(µmol TE/l) 
SD CV% 
Day 1 Intraday 8677,92 214,34 2,47 
Day 2 Intraday 9826,44 279,08 2,84 
Interday mean 
Interday total 
9252,18 
9498,29 
812,13 
595,34 
 
8,78 
6,27 
Tab. 8: Accuracy of the ORAC analyzing 
 
3.3 FRAP – Ferric Reducing Ability of Plasma 
 
3.3.1 The Principle of FRAP 
The FRAP assay, which was developed by BENZIE and STRAIN (1996), 
represents a simple and reliable method to determine the antioxidant capacity 
of biological fluids. The essential mechanism of this procedure is the reduction 
of Fe³+ in consequence of the impact of antioxidant substances as well as due 
to the Fe³+/Fe²+ - Tripyridyltriazin (TPTZ)-redoxsystem, which is the 
subsequent development of a blue colored Iron(II)-complex.  
  
Fig. 10: Reaction of FRAP, [Huang et al., 2005] 
 
The spectrometric measurement of Fe²+ was defined at a low pH-value of 3,6 
and at a wavelength of 593nm. [BENZIE and STRAIN, 1996] This method was 
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adopted and modified for prior analysis at the Department of Nutritional 
Sciences. [VALENTINI, 2009] 
The reaction time was determined at 6 minutes [BENZIE and STRAIN, 1996], 
though the wavelength was altered to 540nm in relation to the filter availability 
of the used apparatus. Furthermore, to increase the throughput rate of the 
samples, 96-well microplates were used. [TSAO et al., 2003] 
The Ferric Reducing Ability of Plasma is a common technique for food extracts 
and pure substances that led to the newly coined term “Ferric Reducing 
Antioxidant Power Assay”. 
 
3.3.2 Reagents and Instruments 
Reagents Chemical Formula Manufacturer 
Sodium acetate trihydrate 
Acetic acid 
6-hydroy-2,5,7,8-
tetramethylchroman-2-carboxylic 
acid (Trolox) 
2-amino, 4, 6-dichloro-s-triazine 
(TPTZ) 
Ferrous(II)-sulphate-heptahydrate 
CH3COONa · 3H2O 
C2H4O2 
                            
C14H18O4 
 
C3H2Cl2N4 
FeSO4 · 7H2O 
 
 
Fluka Chemica 
(CH) 
Iron(III)-chloride-hexahydrate 
Hydrochloric acid 
FeCl3 · 6H2O         
HCl 
 
Riedl de Haen 
(D) 
Apparatus Manufacturer 
FL 600 Microplate Fluorescence 
Reader: FLUOstar Optima 
 
Bio-Tek Instruments 
96-well microplates Sterlin (UK) 
Pipettes (500µl, 1000µl,1200µl, 
5000µl) 
Eppendorf 
Tab. 9: Reagents and Instruments for the FRAP assay 
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Acetate buffer 300mmol/L, pH 3,6: In 1 liter bi-distilled H2O, 3,1g C2H3NaO2 * 3 
H2O and 16ml concentrated acetic acid was dissolved. 
 
TPTZ - solution (10mmol/l in 40 mmol/l HCl): 585µl HCl and 31,2mg 2.4.6-
Tripyridyl-s-triazin was dissolved in 100ml distilled water. 
 
FeCl3 * 6 H2O - solution(20 mmol/l): 54.1mg Iron(III)-chloride was dissolved into 
100ml distilled water. 
 
Frap - solution: 25ml acetate buffer, 2,5ml Iron(III)-chloride and 2,5ml TPTZ-
solution were compounded. (10:1:1) The solution was newly prepared daily and 
stored in a bathwater at 37°C. 
 
FeSO4 * 7 H2O - solution (2000 mmol/l): In 100ml distilled water, 55,6mg 
Iron(II)-sulfate was dissolved to obtain a stock solution, which was further 
diluted into the concentrations of 50, 125, 250, 500, 625, 750 and 1000µmol/l. 
 
Trolox® (Standard): For the stock solution, 62,58mg of Trolox was dissolved in 
100ml of PBS buffer for a concentration of 2500µmol/l and placed in an 
ultrasonic bath until completely dissolved. 1ml of the Trolox stock solution was 
filled in cups and frozen at -20°C for further use. To establish a standard curve, 
the solution was diluted each day before measurement to concentrations of 50, 
100, 200, 300, 400 and 550µmol/l. 
 
Sample Plasma:. Before analyzing, the samples were defrosted and 
centrifuged. 
 
Reference Plasma (Control): To ensure accurate performance, the same 
plasma from a healthy female subject was used for every measurement and 
prepared exactly the same way as the plasma sample 
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3.3.3 Instrument settings 
Test name FRAP 
Mode Absorbance 
Microplate 96-well 
No of cycles 10 
Start measurement 1s 
Cycle time 36s 
Filter and Integration Excitation filter:  540nm 
Incubation On, 37°C 
Shaking options Orbital, 5s, before first cycle 
Tab. 10: Basic Instrument settings FRAP 
 
First, the FLUOstar Optima had to be activated, the appropriate settings 
adjusted and the incubation enabled (37°C). After finishing the   preparation of 
the solutions, the reagents were transferred into the wells of the microplate with 
electronic Eppendorf pipettes. 
 
The blank, standards, controls and samples were analyzed in duplicate. All 
steps summarized in table 11 were considered, beginning with 30µl of distilled 
water in each well, except for the blank where 40µl was applied. The procedure 
then continued as 10µl plasma, standard and/or control were pipetted and 
subsequently, 300µl of preheated (37°C) Frap-solution was added into every 
well. The time between adding the solution and starting the measurement was 
less than one minute. 
 
Reagents / well Standard (µl) Control (µl) Sample (µl) Blank (µl) 
Iron(II)-solution 10    
Trolox®  10   
Plasma   10  
Aqua dest. 30 30 30 40 
FRAP-solution 300 300 300 300 
Tab. 11: Pipetting schemata FRAP 
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Prior to the start of the assay, the microplate reader was adjusted to shake for 5 
seconds and then measure at intervals of 36 seconds for a total duration of 6 
minutes. After shaking had been completed, the final value was obtained, which 
had to be applied against the blank value. An Iron(II)-standard series was used 
simultaneously with samples, blanks and Trolox (control) to quantify the 
concentrations of the antioxidative capacity. 
3.3.4 Work plan for the FRAP assay 
Following the pipette table below, 2 columns of a plate were filled and 
measured while 2 columns of a second microplate were simultaneously 
prepared. This procedure was alternately continued until all samples were 
analyzed. Each plate was completely filled, though only used once. 
 
 
(a) 
 
B…Blank, Fe²+…Control, T…Trolox, S…Sample plasma 
Tab. 12: Layout for the 96-well Microplate FRAP 
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(b) 
 
B…Blank, Fe²+…Control, T…Trolox, S…Sample plasma 
Tab. 13: Layout for the 96-well Microplate FRAP 
3.3.5  Processing of data 
Out of the different absorptions of both the blank and standard solvent Iron(II) 
(50, 125, 250, 500, 625, 750 and 1000µmol/l), a standard curve was 
established. The concentration of the plasma sample (µmol/l) was calculated 
using the linear regression formula (y= k*x+d). 
 
 
Fig. 11: Illustration of the Iron(II)-standard curve (FRAP) 
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Trolox solution was used as a control substance. 
 
 
Fig. 12: Illustration of the Trolox-curve (FRAP) 
 
3.3.6 Quality assurance 
FRAP was measured within a day, therefore control plasma was determined 
tenfold. The table below shows the standard deviation (SD) and the coefficient 
of variation (CV%) of the method. 
 
  
FRAP  
(µmol Fe²+ Eq/l) 
SD 
 
CV% 
 
control (n=10) 426,17 22,29 5,23 
 
Tab. 14: Accuracy of FRAP 
 
3.4 Malondialdehyd (MDA) 
3.4.1 The Principle of MDA 
This method is based on the publications by BANNI and LUCCHI et al. [1996] 
and THOMSON and SMITH [1985]. Sampled plasma is hydrolyzed in the 
presence of phosphoric acid to accumulate a colored complex with 
thiobarbituric acid (TBA), during a one hour heating procedure at 100°C. 
Following the precipitation of plasma proteins in methanol dissolved samples, 
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the MDA-TBA-adducts were separated on the basis of HPLC (emission 563nm; 
excitation 532nm). 
3.4.2 Reagents and Instruments 
Reagents Chemical Formula Manufacturer 
Tetraethoxypropan (TEP) 
Thiobarbituric achid (TBA) 
C7H16O4 
C4H4N2O2S 
 
Sigma-Aldrich 
(D) 
Ethanol 96% p.a. 
Methanol/Sodium Hydroxide 
Methanol chromasolv 
C2H6O 
CH3NaO 
CH3OH 
 
Riedel de Haen 
(D) 
Phosphoric acid (density 1.71 g/ml; 85%)   (H3PO4) 
1 N sodium hydroxide  (NaOH) 
Distilled Water (H2O) 
Apparatus and Manufacturer 
HPLC:            LC-20AT Dual Reciprocating Plunger HPLC Pump 
                       Shimadzu 
Column:         Merck LichroCart 125-4 Lichrospher 100 RP-18 (5µm) 
 
Detector:        Hitachi Model F-1050 Fluorescence Spectrophotometer 
 
Integrator:      Hitachi model D-7500 
Tab. 15: Reagents and Instruments for MDA 
 
 For the eluent (mobile phase): 
Phosphate buffer, pH 6,8: 6.8g of potassium dihydrogen phosphate was 
dissolved in 800ml of distilled water, the pH adjusted to 6.8 and consequently, 
the distilled water increased to 1l. 
 
Eluent’s composition: Phoshate buffer and methanol chromasolv  were mixed at 
a  rate of 60:40. After filtering the eluent through filter paper, it was degassed in 
an ultrasonic bath for 15 minutes. 
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 For the standards: 
Thiobarbituric achid (TBA) solution: 0.6g of TBA was dissolved in 100ml of 
distilled water. 
 
Methanol/Sodium Hydroxide solution: 4.5ml of 1molar sodium hydroxide was 
dissolved in 50ml of methanol chromasolv. 
 
Phosphoric acid solution (0.44 mol/l): 3ml of concentrated ortho-phosphoric acid 
(density 1.71 g/ml; 85%) was mixed with100ml with distilled water. 
1 N sodium hydroxide solution: 4g of caustic soda was dissolved in 100ml of 
distilled water. 
For the stock solution, 50µl of TEP (9% density = 0,92g/ml) was dissolved in 
50ml of ethanol: water solution (40:60), of which 100µl was added to 50ml of 
ethanol: water solution (40:60) for the base material. To establish a standard 
line, the base material was further diluted to concentrations of 0 µM (distilled 
water), 0.195 µM up to 8.12 µM. 
 
3.4.3 Instrument settings 
Autosampler 
 
2 trays; one for 8 standard samples 
and 70 for samples  
Filter  Extinctions filter: 532 nm 
Emissions filter:  563 nm  
Mobile Phase buffer : methanol (60:40) 
Flow Rate 1 ml/min 
Sensitivity 20 
Tab. 16: Basic Instrument settings MDA 
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3.4.4 Implementation 
Reagents /  
pyrex glass 
Blank (µl) Control (µl) Standard (µl) Sample (µl) 
Phosphoric acid 700 700 700 700 
TBA-solution 250 250 250 250 
Water 500 500 500 500 
Distilled water 50    
Reference Plasma  50   
Standard   50  
Sample Plasma    50 
Tab. 17: Pipetting schemata for MDA 
 
The solution was boiled in water for 60 minutes and afterwards cooled down in 
ice water for 10 minutes. Subsequently, 100µl of methanol/sodium hydrogen 
solution were added to the solution in the test tubes. The contained methanol 
denaturized the plasma proteins, and sodium hydroxide neutralized the 
phosphoric acid. Simultaneously there was 100µl of standards or sample pipette 
into the test tubes, followed by the centrifugation of the samples for 2 minutes at 
3000 rpm. With pH indicator paper, the pH was adjusted and 7,2 µl of each 
sample was injected into the HPLC apparatus. 
 
3.4.5 Calculation 
A calibration curve with 8 standards was chosen, and the concentrations were 
calculated using the linear regression formula (y= k*x+d), which was stated in 
µmol MDA/ml plasma. 
3.4.6  Quality assurance 
A control plasma was used daily as an internal standard to verify the accuracy 
of the method and the standard deviation in order to calculate the variation 
coefficient. 
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control MDA (µmol/l) SD CV% 
Day 1 intraday 0,976 0,005 0,5 
Day 2 intraday 0,941 0,041 4,4 
Interday mean 
Interday total 
0,958 
0,958 
0,025 
0,031 
2,6 
3,3 
Tab. 18: Accuracy of MDA 
 
3.5 Statistical evaluation 
The statistical analysis was performed with SPSS Statistics 17.0 for Windows.  
To test on normal distribution, the Kolmogorow-Smirnow-Test (KS-Test) was 
applied. The mean values of the two groups were then compared by utilizing 
both the t-Test and the Mann-Whitney-Test (U-Test).  The t-Test was used for 
independent samples with normal distributed data, and the U-Test was used for 
data that did not follow a normal distribution. Three or more groups were 
compared by using Oneway Anova with the Tukey post hoc test for equal 
variances and the Tamhane’s T2 for non-homogenous data. To determine 
correlations between different groups, the “Pearson Correlation” and the 
“Spearman Correlation” were performed, dependent on the normal distribution.  
All data are shown as mean values ± standard deviation. The significant 
differences were expressed as significant (p<0,05)*, highly significant 
(p<0,01)**, and very highly significant (p<0,001)***.  If a trend was observed, it 
was marked as (p=0,05 – 0,10)#. 
 
4 Results and Discussion 
4.1 Study characteristics 
100 subjects participated in the study, 76 of which successfully completed both 
the evaluation and met the inclusion criteria. The 76 individuals were then 
divided into two groups, the GS group, which was defined by UCB levels at or 
over 17 µmol/l, and the healthy control group with had UCB levels under 17 
µmol/l.  Each group included 28 male and 10 female individuals. 
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  N Male Female Age (mean±SD) BMI (mean±SD) 
GS 38 28 10 32,3 ± 11,76 22,8 ± 2,85 
Control 38 28 10 31,9 ± 11,23 24,3 ± 3,21 
Total 76 56 20 32,1 ± 11,42 23,6 ± 3,12 
 
Tab. 19: Study characteristics of the GS and control group 
 
The measured UCB levels in the total group ranged from 4,10 µmol/l to 73,53 
µmol/l, which is analog to the results of BOON et al. [2012] with UCB 
concentrations between 5,1 and 85,3 µmol/l.  With p<0,001, the GS group 
showed significantly higher UCB levels (32,0 ± 13,64 µmol/l) compared to the 
control group (10,3 ± 3,31 µmol/l). 
 
 mean ± SD UCB (µmol/l) Ranges (µmol/l) Male (56) Female (20) 
GS 32,0 ± 13,64 17,10 - 73,53 33,6 ± 14,86 27,3 ± 8,33 
Control 10,3 ± 3,31 4,10 - 15,90 11,2 ± 2,89 7,8 ± 3,24 
 
Tab. 20: Average UCB concentrations and ranges in GS and control group 
 
The recorded UCB concentration roughly corresponds to the results of VITEK 
et. al, who detected significantly higher serum bilirubin levels in GS subjects 
with 27,8 ± 9,7µmol/l, compared to the control group with 9,9 ± 3,0 µmol/l. 
[2007] 
4.2 Evaluation of the used methods ORAC, FRAP and MDA 
In the following chapters, the results of ORAC, FRAP and MDA are discussed; 
hence, the study population was subdivided into different groups to determine 
potential distinctions based on gender, age, body mass index and UCB.  ORAC 
values are expressed in µmol Trolox Equivalent (TE)/l, and FRAP levels are 
expressed in µmol Fe²+ Equivalent/l.  However, for convenience, the data are 
stated as µmol/l.  To our knowledge, ORAC was never before used in context 
with GS. 
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4.2.1 Differences between the GS and control group  
The study population was divided into a healthy control group and a GS group 
in order to determine the differences. 
 
mean ± SD  
(µmol/l)  GS  Control  p-value 
N 38 38 - 
ORAC  9144 ± 822 9420 ± 1130 0,23 
FRAP  548 ± 59 440 ± 55 < 0,001*** 
MDA  0,825 ± 0,339 0,785 ± 0,234 0,55 
    Tab. 21: ORAC, FRAP and MDA levels in GS and control group 
 
ORAC and MDA showed no significant differences between the GS and control 
group. However, FRAP exhibited very highly significant elevated concentrations 
compared to the healthy control group (p<0,001). This is according to the 
results of BLUMER et al. who discovered significant increased FRAP levels 
(p<0,05), although there were no significant lower MDA plasma levels (p=0,500) 
in the GS group. [2008] 
 
 
Fig. 13: Difference of the FRAP levels between GS and control group 
 
*** (GS < control ; p < 0,001) 
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4.2.2 UCB (unconjugated bilirubin) in Tertiles 
The entire study population was divided into different UCB-tertiles to detect the 
different effects.  The UCB-ranges were separated into 3 groups: 
 
 Tertile 1 (<12µM): low bilirubin levels 
 Tertile 2 (12,5-21,4µM): moderate bilirubin levels 
 Tertile 3 (>21,4µM): high bilirubin levels 
 
mean ± SD  
(µmol/l) Tertile 1 Tertile 2 Tertile 3 p-value 
N 26 25 25 - 
Age 31,5 ± 11,1 30,7 ± 11,6 34,1 ± 11,8 0,555 
UCB range  4,10 - 12,48 12,65 - 21,38 22,06 - 73,53 - 
ORAC  9490 ± 1118 9092 ± 1037 9257 ± 782 0,358 
FRAP  427 ± 55 487 ± 44 571 ± 55 < 0,001*** 
MDA  0,795 ± 0,242 0,798 ± 0,245 0,823 ± 0,376 0,933 
 
  
 
  
 Tab. 22: ORAC, FRAP and MDA levels divided into UCB tertiles 
 
The ORAC and MDA levels showed no significant differences between the 
three UCB ranges. The FRAP data present a very high significant difference 
between all bilirubin tertile groups (p<0,001).  Thus, leading to the conclusion 
that the FRAP levels and consequently, the antioxidant capacity increases in 
correlation to elevated UCB levels. 
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Fig. 14: FRAP values according to the different UCB tertiles 
4.2.3 UCB in Quartiles 
The study population was further divided into UCB-Quartiles: 
 Quartile 1 (<10µmol/l): 4,10 – 8,21 µmol/l 
 Quartile 2 (10 – 17,1µmol/l): 10,26 – 17,10µmol/l 
 Quartile 3 (17,2 – 36µmol/l): 17,78 – 35,40µmol/l 
 Quartile 4 (≥ 36 µmol/l): 36,77 – 73,53µmol/l 
 
mean ± SD 
(µmol/l) Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value 
N 16 23 23 14 - 
Age 33,0 ± 12,3 30,8 ± 10,5 31,4 ± 10,9 34,4 ± 13,6 0,800 
UCB 
range 4,10 - 8,21 10,26 - 17,10 17,78 - 35,40 36,77 - 73,53 - 
ORAC 9115 ± 1039 9612 ± 1147 9054 ± 856 9305 ± 802 0,240 
FRAP 421 ± 60 453 ± 47 529 ± 56,8 585 ± 39 <0,001*** 
MDA  0,826 ± 0,274 0,766 ± 0,204 0,830 ± 0,366 0,805 ± 0,311 0,885 
 
Tab. 23: ORAC, FRAP and MDA levels divided into UCB-quartiles 
There were no significant differences between the four UCB groups in ORAC 
and MDA.  The FRAP values were very highly significant different within all 
*** (T1 < T2 < T3; p < 0,001) 
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quartiles (p<0,001).  The levels showed a considerable increase from the first to 
the forth quartile (Quartile 1 < Quartile 2 < Quartile 3 < Quartile 4). 
4.2.4 Differences between gender 
Due to an existing gender bias in GS (~25%) the study population was 
subdivided into men and women to establish occurring distinctions. [VITEK  et 
al. 2002] 
mean ± SD 
(µmol/l) Male Female p-value 
N 56 20 - 
Age 31,5 ± 11,4 33,9 ± 11,7 0,426 
UCB  22,4 ± 15,5 17,5 ± 11,6 0,184 
ORAC  9368 ± 953 9043 ± 1082 0,212 
FRAP  505 ± 64 462 ± 104 0,033* 
MDA  0,797 ± 0,299 0,828 ± 0,268 0,681 
 
Tab. 24: ORAC, FRAP and MDA levels considering gender 
The UCB and ORAC levels were slightly higher, and the MDA levels were 
marginally lower in male subjects, everything not significant. Only FRAP 
showed significantly (p < 0,05) higher levels in men (505 ± 64), compared to 
female subjects (462 ± 104). This might indicate that men, due to an increased 
bilirubin level, have a higher antioxidative capacity and correspondingly, less 
oxidative damage.  
Male subjects generally show higher bilirubin concentrations (12,4%), and are 
more often affected by GS when compared to females (4,8%).  An explanation 
might be the increased bilirubin load per kilogram body weight in men, as well 
as an inhibition of the enzymatic glucuronidation of bilirubin, due to androgen 
steroids. [RADU and ATSMON 2001] 
A Slovakian study that investigated the effect of mineral wool exposure on 
oxidative DNA damage and lipid peroxidation, found no differences between the 
exposed and the control group, however, general male individuals showed 
significantly higher concentrations of FRAP than female subjects, which is 
similar to our outcome. [STARUCHOVA et al., 2008] 
54 
 
4.2.5 Differences between 2 groups BMI 
 
mean ± SD 
(µmol/l) 
BMI < 
25 kg/m² 
BMI ≥ 
25 kg/m² 
p-value 
 
N 53 23 - 
Age (years) 29,7 ± 9,9 37,7 ± 13,0 0,005** 
UCB  29,3 ± 12,3 10,1 ± 3,2 < 0,001*** 
ORAC  9127 ± 888 9640 ± 1139 0,038* 
FRAP  502 ± 81 474 ± 70 0,156 
MDA  0,821 ± 0,291 0,768 ± 0,291 0,466 
 
Tab. 25: ORAC, FRAP and MDA levels divided into 2 BMI groups 
In the total study population, more subjects had a normal body mass index < 25 
kg/m² than an increased BMI ≥ 25 kg/m², (approximate ratio= 2:1).  The group 
with elevated BMI levels (37,7 ± 13,0) was significantly older (p=0,005), 
compared to the group < 25 kg/m² (29,7 ± 9,9), which is evidence that the BMI 
is increasing with the advancement of age.  
MDA and FRAP showed no significant differences between the two categories, 
although FRAP hints at slightly higher values in the group < 25 kg/m² (502,1 ± 
81,1µmol/l), compared to the group ≥ 25 kg/m² (474,2 ± 69,7µmol/l).  
The UCB levels are highly significantly increased in subjects with a BMI < 25 
kg/m² (p<0,001***), which leads to the conclusion that patients with GS 
generally have normal bodyweight and, are therefore not overweight or obese.  
Interestingly, opposite to former results, the ORAC values were significantly 
lower (p=0,038) in the group < 25 kg/m² (9127 ± 888 µmol/l), compared to the 
overweight group (9640 ± 1139 µmol/l), which subsequently showed a higher 
antioxidant capacity.  A possible reason for the elevated data in overweight 
subjects might be the increased serum lipid level, which is able to bind and 
neutralize circulating endotoxins, and therefore, inhibit the subsequent 
stimulation of inflammatory cytokines. Furthermore, a higher production of 
soluble TNF-α receptor neutralizes the inflammatory effect of TNF-α. Another 
explanation might be the ability of adipose tissue to neutralize toxic metabolites 
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and the antioxidative effect of the musculature. Thus, an increased BMI in 
subjects with higher age does not necessarily lead to a higher mortality rate.  
For individuals over 65 years of age, a BMI of 27 – 30 kg/m² was established to 
be in correlation to the mortality risk. Therefore, a BMI ≥ 25 kg/m² proved to be 
advantageous, especially in elderly people with diseases, such as chronic 
inflammation, chronic heart failure, renal failure and rheumatoid arthritis. 
[DORNER and RIEDER, 2010] 
 
4.2.5.1 Differences between GS and C group divided in 2 groups BMI 
 
mean ± SD 
(µmol/l) 
GS < 25 
kg/m² 
C < 25 
kg/m² 
GS ≥ 25 
kg/m² 
C ≥ 25 
 kg/m² p-value 
N 30 23 8 15 - 
UCB  29,3 ± 12,3 10,1 ± 3,2 35,6 ± 10,5 21,1 ± 14,7 < 0,001*** 
ORAC  9015 ± 847 9273 ± 937 9630 ± 516 9645 ± 1381 0,160 
FRAP  550 ± 62 440 ± 58 540 ± 47 439 ± 53 < 0,001*** 
MDA  0,818 ± 0,322 0,825 ± 0,251 0,853 ± 0,418 0,722 ± 0,197 0,665 
 
Tab. 26: ORAC, FRAP and MDA levels divided into GS, control and 2 BMI groups 
MDA showed no significant differences within the groups. ORAC indicated a 
slight but not significant difference between the GS group < 25 kg/m² (9015 ± 
847) and the control group ≥ 25 kg/m² (9645 ± 1381).  The UCB and FRAP 
results significantly differed between the GS and control groups. 
 
4.2.6 Differences between age in 2 groups 
Age can possibly influence the antioxidant capacity and oxidative damage. 
Therefore, the study population, which ranged from 20-67 years, was separated 
into a younger group with individuals < 30 years and an older group ≥ 30 years. 
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mean ± SD < 30 years  ≥ 30 years p-value 
N 43 33 - 
Range (years) 20 - 29 30 - 67 - 
UCB (µmol/l) 19,9 ± 13,2 22,7 ± 16,5 0,417 
ORAC (µmol/l) 9030 ± 869 9610 ± 1057 0,011* 
FRAP (µmol/l) 492 ± 77 496 ± 81 0,825 
MDA (µmol/l) 0,803 ± 0,240 0,807 ± 0,348 0,955 
    Tab. 27: ORAC, FRAP and MDA levels divided into 2 age groups 
No significant differences were found in FRAP, MDA and UCB levels.  ORAC 
was significantly higher (p=0,011*) in subjects ≥ 30 years (9610 ± 1057 µmol/l), 
in comparison to the younger subgroup (9030 ± 869 µmol/l).  
4.2.6.1 Differences between GS and C group divided in 2 age groups 
For further evaluation the two age groups were stratified for GS and control 
group. 
 (µmol/l) 
 
GS < 30 
years 
C < 30  
years 
GS ≥ 30 
years 
C ≥ 30  
years p-value 
N 22 16 21 17 - 
UCB  29,3 ± 12,3 10,1 ± 3,2 35,6 ± 10,5 21,1 ± 14,7 < 0,001*** 
ORAC  8881 ± 803 9187 ± 927 9507 ± 725 9708 ± 1312 0,048* 
FRAP  542 ± 578 440 ± 59 556 ± 61,5 440 ± 52 < 0,001*** 
MDA  0,786 ± 0,277 0,821 ± 0,199 0,879 ± 0,412 0,739 ± 0,270 0,566 
 
Tab. 28: ORAC, FRAP and MDA levels divided into GS, control and 2 age groups  
There were no significant differences observed in MDA concerning the GS, the 
control group and age.  FRAP and UCB data was highly significantly increased 
(p<0,001) in GS under and over 30 years, compared to both the younger and 
the older control group.  ORAC was significantly higher in GS < 30 years than in 
the control group ≥ 30 years (p=0,045). 
4.3 Correlations 
Correlations between the methods ORAC, FRAP, MDA and various clinical and 
biochemical parameters were calculated. In the following chapters the most 
significant correlations are discussed. 
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4.3.1 Correlations with ORAC 
4.3.1.1 ORAC and UCB 
There was no significant correlation between ORAC and UCB in the total study 
population (r=0,068, p=0,746), as well as in the GS and control group. 
4.3.1.2 ORAC and uric acid 
 
  r-value p-value 
total 
population 0,256 0,025* 
GS  0,205 0,218 
control 0,338 0,038* 
 
Tab. 29: Correlation between ORAC and uric acid  
 
A minor significant positive relationship between ORAC and uric acid was 
observed in the whole study cohort. (r=0,256, p=0,025*) ORAC exhibited no 
significant correlation with uric acid in the GS group (r=0,205, p=0,218), 
however in the control group a more potent significant correlation was found. 
(r=0,338, p=0,038*) 
   
 
Fig. 15: Correlation between ORAC and uric acid in (a) the whole cohort and (b) control  
 
r = 0,256 r = 0,338 
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Uric acid is a potent natural antioxidant and is responsible for up to 60% of the 
free radical scavenging activity in human blood. [AMES et al., 1981]  Elevated 
plasma levels of uric acid are further linked with markers for CVD.  However, it 
is not clear if the increased concentrations are based on a protective antioxidant 
response to augmented oxidative stress or constitute a cause of CVD.  
Therefore, uric acid might provide antiatherosclerotic activity on the one hand, 
and exhibit proatherogenic effects at increased concentrations on the other 
hand. [GAGLIARDI et al. 2009, KAYA et al. 2010]  A recent study suggested 
that uric acid serves as a substrate for myeloperoxidase, and the subsequent 
formed uric acid radical could influence atherogenic and inflammatory 
processes due to reactions with O2* and NO*. [MEOTTI et al., 2011] 
4.3.1.3 ORAC and BMI  
ORAC showed a slight but significant positive correlation with the body mass 
index in the total study population (r=0,269, p=0,019), with a middle strong 
correlation in the 3.UCB-tertile (r=0,419, p=0,037).  A positive correlation of 
ORAC and BMI in male subjects proved to be significant (r=0,324, p=0,015), 
opposite to the ORAC levels of females, which indicated no significant 
correlation (r=0,120, p=0,614).  In the GS group, the correlation was somewhat 
stronger (r=0,350, p=0,038), whereas the control group showed no significant 
relationship (r=0,177, p=0,289). 
  
 
Fig. 16: Correlation of ORAC and BMI in (a) the whole cohort and (b) 3. UCB-tertile 
 
r = 0,269 r = 0,419 
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4.3.2 Correlations with FRAP 
4.3.2.1 FRAP and UCB 
  r-value p-value   r-value p-value 
total population 0,812 <0,001*** BMI < 25 0,832 <0,001*** 
GS  0,696 <0,001*** BMI ≥ 25 0,672 <0,001*** 
control 0,451 <0,001*** 1. Tertile 0,351 0,079# 
male 0,777 <0,001*** 2. Tertile  0,547 0,005** 
female 0,877 <0,001*** 3. Tertile 0,431 0,031* 
< 30 years 0,837 <0,001*** ≥ 30 years 0,767 <0,001*** 
Tab. 30: Correlation between FRAP and UCB in various groups 
 
FRAP and UCB showed a highly significant positive correlation in all groups, 
except for the lowest UCB-tertile, where there was no significant correlation, but 
a tendency (r=0,351, p=0,079#). This indicates a higher antioxidant capacity in 
GS subjects due to an elevated UCB status. 
 
 
Fig. 17: The relationship between FRAP and UCB in the whole cohort  
 
r = 0,812 
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4.3.2.2 FRAP and Albumin 
  r-value p-value 
total 
population 0,302 0,008** 
control 0,375 0,020* 
female 0,501 0,024* 
< 30 years 0,498 0,001** 
BMI < 25 0,336 0,014* 
1. UCB-Tertile 0,394 0,046* 
Tab. 31: Correlations between FRAP and Albumin in various groups 
 
Amongst the entire cohort, a positive highly significant relationship was detected 
between FRAP and albumin (r=0,302, p=0,008).  The correlation proved to be 
strongest in females (r=0,501, p=0,024) and in subjects < 30 years (r=0,498, 
p=0,001). 
 
 
Fig. 18: Correlation between FRAP and albumin in (a) females and (b) <30 years 
 
Like uric acid, albumin acts as an important contributor to the total antioxidant 
status in humans. [CAO and PRIOR, 1998]  As previously mentioned, albumin 
serves as a transporter for the hydrophobic unconjugated bilirubin in plasma 
and therefore, increased albumin concentrations are associated with elevated 
levels of bilirubin. STOCKER et al. [1987] proved that one mole of albumin-
bound bilirubin scavenges two moles peroxyl radicals in competition with uric 
r = 0,501 r = 0,498 
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acid. Albumin-bound bilirubin protects linoleic acid as well as the albumin 
molecule itself from peroxidation. In absence of antioxidants, the amino acids of 
albumin are attacked by OH* and O2* radicals. However, if UCB is present, the 
attacked amino acids decrease by half, which indicates a more potent effect in 
preventing protein damage in comparison to vitamin E and trolox. [NEUZIL  et 
al., 1993] 
4.3.3 Correlations with MDA 
4.3.3.1 MDA and UCB 
There were no significant correlations between UCB and plasma MDA in the 
whole cohort (r=0,032, p=0,782). The outcome is similar to Blumer et al. [2008], 
who found no significant differences in the oxidative stress marker MDA in the 
GS and control group (p=0,500). 
MDA is a commonly used method to measure the antioxidant status in infants 
with hyperbilirubinemia.  Compared to adults, infants with increased bilirubin 
levels show a prolonged lag phase and a reduced slope of serum oxidation. 
[WIEDERMANN et al., 2003]  
 
KUMAR et al. investigated the influence of bilirubin as an antioxidant in 
newborns with increased bilirubin levels by assessing MDA as a marker of 
oxidative stress. Jaundiced neonatal subjects showed significantly lower MDA 
levels. Moreover, plasma bilirubin exhibited a significant negative correlation 
with antioxidant enzyme activities, which led to the conclusion that neonatal 
hyperbilirubinemia is associated with decreased oxidative stress. [2007] 
However, another study discovered elevated MDA concentrations and a 
positive correlation between MDA and bilirubin levels in infants with manifest 
hyperbilirubinemia, due to hemolysis compared to a healthy control group. 
[YIGIT et al., 1999]  
 
Therefore, a recent study investigated the reason of the different outcomes and 
came to the following conclusion: the antioxidant effect of bilirubin is linked to 
the concentration until a certain threshold, after which kernicterus is developed 
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with a toxic impact on cells. Hence, further research is necessary to investigate 
the point at which bilirubin shows a toxic effect when it passs the blood-brain-
barrier. [DOGAN et al., 2011] 
 
4.3.3.2 MDA and high density lipoprotein (HDL) 
  r-value p-value   r-value p-value 
total 
population 0,313 0,007** BMI < 25 0,300 0,032* 
GS  0,301 0,070# BMI ≥ 25 0,341 0,112 
control 0,368 0,025* 1. Tertile 0,459 0,018* 
male 0,260 0,058# 2. Tertile  0,429 0,036* 
female 0,563 0,010* 3. Tertile 0,208 0,330 
< 30 years 0,196 0,213 ≥ 30 years 0,439 0,012* 
Tab. 32: Correlation between MDA and HDL in various groups 
 
There was a weak but highly significant positive relationship between MDA and 
HDL in the whole cohort observed (r=0,313, p=0,007). Higher levels of HDL are 
associated with elevated values of MDA and, therefore lead to an increased 
lipid peroxidation. In male subjects, there was no significant correlation, 
although a strong trend (r=0,260, p=0,058#) was found.  In the GS group, no 
significant relationship was exhibited either (r=0,301, p=0,070#), which might be 
due to the fact that more men than women have GS (28 males : 10 females).  
The female population indicated the strongest correlation between MDA and 
HDL (r=0,563, p=0,010), which leads to the conclusion that women manifest a 
more potent lipid peroxidation compared to men, which is explainable by the 
higher HDL concentration in women. 
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Fig. 19: Correlation between MDA and HDL in the whole study population 
 
High-density lipoprotein exhibits a protective role in the development of 
coronary heart disease and therefore, low plasma concentrations of HDL 
indicate a risk factor. The protective effect has been attributed in part in the 
reverse cholesterol transport, a multi-level process in which cholesterol is 
carried by plasma compartment from peripheral tissues back to the liver. 
[OLLSON, 2009] Moreover, HDL particles contain various elements that might 
account to cardioprotection through antioxidant, antithrombotic, anti-
inflammatory and endothelial stabilizing effects. [BARTER et al., 2004] 
However, doubts about the beneficial attributes of HDL have arisen.  ANSELL 
et al. [2007] suggested that HDL have either anti-inflammatory or pro-
inflammatory properties, depending on whether proteins, enzymes or lipids are 
transported.  Due to specific pathologic chemical and structural changes, HDL 
particles become dysfunctional, pro-inflammatory and lose the ability to 
decrease the oxidation of LDL.  HDL particles also control the reverse 
cholesterol transport and suppress vascular inflammation. Patients with 
coronary heart disease exhibit HDL particles with pro-inflammatory properties 
independent of the HDL concentration. However, a high HDL is still considered 
as protective against CVD by several associations (e.g. American Heart 
Association (AHA)). 
r = 0,313 
r = 0,563 
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4.3.3.3 MDA and total cholesterol (TCH) 
  r-value p-value   r-value p-value 
total 
population 0,322 0,005** BMI < 25 0,369 0,008** 
GS  0,326 0,049* BMI ≥ 25 0,341 0,112 
control 0,349 0,034* 1. Tertile 0,478 0,018* 
male 0,228 0,097# 2. Tertile  0,429 0,034* 
female 0,584 0,007** 3. Tertile 0,197 0,355 
< 30 years 0,478 0,001** ≥ 30 years 0,203 0,264 
Tab. 33: Correlation between MDA and HDL in various groups 
 
A highly significant positive correlation between MDA and TCH in the whole 
study population was detected (r=0,322, p=0,005).  The strongest relationship 
was found in female subjects (r=0,584, p=0,007), oposite to male individuals, 
who showed only a weak trend (r=0,228, p=0,097#).  In the GS group, there was 
more or less the same trend observed (r=0,326, p=0,049) as in the control 
group (r=0,349, p=0,034). 
  
 
Fig. 20: Correlation between TCH and MDA in (a) the whole cohort and (b) females 
 
Cholesterol, a waxy fat steroid component of mammalian membranes, is an 
important factor of human health.  However, increased concentrations in the 
blood have been strongly associated with damage to arteries and 
cardiovascular diseases. The majority of total serum cholesterol is contained in 
r = 0,322 r = 0,584 
65 
 
 
low-density lipoprotein (LDL). Therefore, in various epidemiological studies a 
strong relationship between total cholesterol and coronary heart disease was 
found, which indicates that elevated LDL exhibits a powerful risk factor.  Further 
it is revealed as the most frequent evident atherogenic lipoprotein, which is 
affirmed by significant elevation of LDL cholesterol in homozygous and 
heterozygous genetic disorders of familial hypercholesterolemia with an 
accelerated atherogenesis. [NCEP, 2002] 
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5 Conclusion 
The present work aimed to analyze whether or not GS subjects exhibit an 
advanced protection against oxidative damage and subsequently, possess a 
superior antioxidant capacity. Thus, different assays with diverse mechanisms 
to determine the antioxidative capacity and oxidative stress caused by lipid 
peroxidation were used.  
Whilst ORAC and MDA showed no significant differences between GS and 
control group, FRAP was significantly higher in GS. Furthermore, FRAP levels 
proved to be significantly linked to UCB through a simultaneous rise in 
concentration. Male subjects are more often affected by GS and showed 
elevated FRAP levels due to generally increased UCB concentrations and 
hence, manifest an elevated antioxidant capacity. A significantly positive 
relationship between FRAP and albumin was detected, which was strongest in 
women and individuals < 30 years of age and most presumably resulted from 
the fact that albumin acts as a transporter for UCB in plasma.  
Interestingly, significantly higher ORAC levels in individuals ≥ 30 years of age 
and a significant correlation between ORAC and subjects with a BMI ≥ 25kg/m² 
was found. Moreover, ORAC was significantly positive correlated with uric acid 
in the control group compared to the GS population. This suggests that in 
healthy people, uric acid is the predominant antioxidant in human serum while 
in GS subjects, the competitive UCB is more dominant.  
MDA was positively correlated with HDL and total cholesterol, especially in the 
female cohort, which proved a major susceptibility to oxidative damage in 
women in comparison to males.  
The results of this study showed that females possess a higher potential for 
oxidative stress than do males. The GS subjects had significantly higher FRAP 
values than the age and sex matched healthy control group, which positively 
correlates with the elevation of UCB concentrations and therefore demonstrates 
that individuals with GS have a higher antioxidant capacity due to increased 
UCB.  
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6 Summary 
In various studies, bilirubin has been proven to be an effective antioxidant with 
the potential to decrease the prevalence of oxidative stress-induced diseases. 
Therefore, it is assumed that individuals with GS exhibit a minor susceptibility to 
oxidative damage and subsequent diseases due to an elevated bilirubin status 
compared to healthy subjects.  
The present case-control-study, which was funded by the FWF-Austrian 
Science Fund (project number P21162), aimed to investigate the antioxidant 
status of individuals with GS, a benign hyperbilirubinemia, compared to a group 
of healthy age and gender matched control subjects. 104 subjects were 
recruited and 76 of them divided according to their unconjugated serum bilirubin 
concentrations into an affected GS group and the control group.  
To determine the antioxidant capacity the ORAC and FRAP assayes were 
applied, and to further measure oxidative stress due to lipid peroxidation, the 
biomarker MDA was investigated. The outcome was not consistent, which might 
be a result of the different mechanisms of the used methods and moreover, a 
diverse affinity to the endogenous antioxidant bilirubin. Whilst ORAC and MDA 
showed no differences in the GS and control group, FRAP levels were 
significantly higher in GS subjects and exhibited a significantly positive 
correlation with UCB, which indicated a higher antioxidant capacity in GS based 
on increased UCB concentrations. Our findings therefore support the 
hypothesis that individuals with elevated UCB levels possess an improved 
protection against oxidative stress and subsequent diseases. 
A significant relationship between ORAC and uric acid was discovered in the 
control group which suggests a predominance of uric acid in plasma of healthy 
individuals, contrary to GS subjects with bilirubin acting as predominating 
antioxidant. 
. 
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7 Zusammenfassung 
Unterschiedliche Studien konnten die antioxidative Wirkung von Bilirubin und 
dessen Potential für die Risikominderung von oxidativen Stress bedingten 
Erkrankungen belegen. Daher wird angenommen, dass Personen mit erhöhten 
Plasmabilirubinwerten (= Gilbert Syndrome, GS) im Vergleich zu gesunden 
Personen eine geringere Empfänglichkeit gegenüber oxidativer Schädigung und 
einhergehenden Krankheiten besitzen. 
Die aktuelle Fall-Kontroll-Studie, welche vom Österreichischen 
Wissenschaftsfonds (FWF, Projektnummer P21162) gefördert wurde, hatte das 
Ziel den antioxidativen Status von Personen mit GS, einer leichten 
Hyperbilirubinämie im direkten Vergleich zu gesunden Kontroll-Personen zu 
untersuchen. Dafür wurden 104 Personen rekrutiert und 76 von ihnen aufgrund 
ihrer unkonjugierten Serum-Bilirubinkonzentrationen in eine GS- und eine 
alters- und geschlechtsangepasste gesunde Kontroll-Gruppe unterteilt.  
Um die antioxidative Kapazität zu messen, wurden die Methoden ORAC und 
FRAP angewandt und um den oxidativen Stress zu beurteilen, wurde der 
Biomarker MDA untersucht. Die Ergebnisse waren unterschiedlich, was 
möglicherweise auf die verschiedenen Mechanismen der Methoden und deren 
unterschiedliche Affinität zu Bilirubin zurückzuführen ist. Während ORAC und 
MDA keine Unterschiede zwischen der GS- und Kontroll-Gruppe aufwiesen, 
waren die FRAP Werte bei den GS Personen signifikant erhöht und zeigten 
eine positive Korrelation mit unkonjungiertem Bilirubin (UCB). Dies weist auf 
eine gesteigerte antioxidative Kapazität bei Personen mit GS hin, die auf eine 
erhöhte UCB Konzentration zurückzuführen ist. Die vorliegenden  Ergebnisse 
stützen daher die Hypothese, dass Menschen mit erhöhten UCB Werten einen 
besseren Schutz gegenüber oxidativem Stress und dessen Folgeerkrankungen 
besitzen.  
Eine signifikant positive Korrelation zwischen ORAC und Harnsäure in der 
Kontroll-Gruppe zeigt das Potential von Harnsäure im Plasma, was sich in der 
Gruppe der GS zu Gunsten von erhöhtem UCB verschiebt. 
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